





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/11, 15/85, C12Q 1/68, C07K 14/47		A1	(11) International Publication Number: WO 95/06118
			(43) International Publication Date: 2 March 1995 (02.03.95)
(21) International Application Number: PCT/US94/09395		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 19 August 1994 (19.08.94)			
(30) Priority Data: 08/110,158 20 August 1993 (20.08.93) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(60) Parent Application or Grant (63) Related by Continuation US 08/110,158 (CIP) Filed on 20 August 1993 (20.08.93)			
(71) Applicant (for all designated States except US): BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA [US/US]; 600 Parrington Oval, Norman, OK 73109 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): McEVER, Rodger, P. [US/US]; 1716 Guilford Lane, Oklahoma City, OK 73120 (US). PAN, Junliang [CN/US]; Apartment 2714, 2301 North West, 122 nd Street, Oklahoma City, OK 73120 (US).			
(74) Agent: PABST, Patrea, L.; Kilpatrick & Cody, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309-4530 (US).			
(54) Title: EXPRESSION CONTROL SEQUENCES OF THE P-SELECTIN GENE			


WILD-TYPE



MUTANT



RELATIVE LUCIFERASE ACTIVITY



(57) Abstract

DNA molecules and methods for the regulated expression of a gene in endothelial cells or megakaryocytes, are described, wherein the 5' flanking region of the P-selectin gene, or portions thereof, is ligated to the 5' end of a gene. The DNA molecules are also used as probes for screening individuals with abnormal levels of expression of P-selectin, or for production of pharmaceutical compositions to inhibit inflammation by inhibition of expression of P-selectin. These DNA molecules can also be used to identify and isolate previously unknown proteins which are involved in regulation of gene expression.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

EXPRESSION CONTROL SEQUENCES OF THE P-SELECTIN GENE

Background of the Invention

5 This invention is generally in the field of
compositions and methods for the treatment and
prevention of inflammatory responses involving P-
selectin (formerly, GMP-140 or PADGEM) binding
reactions, particularly adhesive interactions
between platelets, leukocytes, and endothelial
10 cells.

The adherence of leukocytes to vascular
surfaces is a critical component of the
inflammatory response, and is part of a complex
series of reactions involving the simultaneous and
15 interrelated activation of the complement,
coagulation, and immune systems. Leukocyte
adherence to vascular endothelium is a key initial
step in migration of leukocytes to tissues in
response to microbial invasion. The initial
20 rolling contacts of leukocytes with the endothelium
are mediated by the selectins, a family of
receptors that interact with cell-surface
carbohydrate ligands (reviewed in McEver, *Curr.*
Opin. Cell Biol., 4, pages 840-859 (1992); Lasky,
25 *Science*, 258, pages 964-969, (1992)). These
transient adhesive interactions allow time for
leukocytes to become activated by signaling
molecules that are released from the endothelium or
the underlying tissues. Upon activation,
30 leukocytes functionally upregulate members of the
integrin family of adhesion receptors. The
integrins strengthen adhesion by binding to
immunoglobulin-like counter-receptors on the
endothelial cell (McEver, *Curr. Opin Cell Biol.*, 4,
35 pages 840-859 (1992)). Adhesion and signaling
molecules function cooperatively to regulate
leukocyte recruitment during the inflammatory
response.

Leukocytes also adhere to activated platelets, through interactions of P-selectin on the activated platelet surface with carbohydrate ligands on the leukocyte surface (McEver, in Structure, Function, and Regulation of Molecules Involved in Leukocyte Adhesion, pages 135-150 (Lipsky et al., eds., Springer-Verlag, New York, 1993)). Platelet-leukocyte interactions may serve as important links between the hemostatic and inflammatory responses to tissue injury.

The coagulation and inflammatory pathways are regulated in a coordinated fashion in response to tissue damage. For example, in addition to becoming adhesive for leukocytes, activated endothelial cells express tissue factor on the cell surface and decrease their surface expression of thrombomodulin, leading to a net facilitation of coagulation reactions on the cell surface. In some cases, a single receptor can be involved in both inflammatory and coagulation processes. For example, the Mac-1 receptor on leukocytes, a member of the CD11-CD18 group, mediates phagocytosis and serves as a receptor for the degradation product of complement C3bi, is involved in one pathway of adherence of leukocytes to endothelium, mediates granulocyte aggregation, and binds coagulation Factor X.

Proteins involved in the hemostatic and inflammatory pathways are of interest for diagnostic purposes and treatment of human disorders. An example is P-selectin, formerly known as GMP-140 (granule membrane protein 140) or PADGEM, an integral membrane glycoprotein with an apparent molecular weight of 140,000 as assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). P-selectin contains an N-terminal lectin-like domain, followed by an

epidermal growth factor-like module, a series of consensus repeats related to those in complement-binding proteins, a transmembrane domain, and a cytoplasmic tail, as described in the parent application, United States Serial No. 07/320,408, filed March 8, 1989, the teachings of which are incorporated herein. P-selectin is a member of the selectin family of adhesion receptors that mediate leukocyte interactions with vascular endothelium or platelets (McEver, *Curr. Opin. Cell Biol.*, 4, pages 840-849 (1992); Lasky, *Science*, 258, pages 964-969 (1992); Bevilacqua and Nelson, *J. Clin. Invest.*, 91, pages 379-387 (1993)). The human P-selectin gene spans over 50 kilobases (kb) and contains 17 exons, most of which encode structurally distinct domains (Johnston et al., *J. Biol. Chem.*, 265, pages 21381-21385 (1990)).

P-selectin was first purified (as GMP-140) from human platelets by McEver and Martin, *J. Biol. Chem.*, 259, pages 9799-9804 (1984). Monoclonal and polyclonal antibodies to P-selectin were also prepared, as reported by McEver and Martin (1984) and P.E. Stenberg, et al., *J. Cell Biol.*, 101, pages 80-886 (1985). The protein is present in alpha granules of resting platelets but is rapidly redistributed to the plasma membrane following platelet activation, as reported by Stenberg, et al., (1985). The presence of P-selectin in endothelial cells and its biosynthesis by these cells was reported by McEver, et al., *Blood*, 70(5) Suppl. 1:355a, Abstract No. 1274 (1987). In endothelial cells, P-selectin is found in storage granules known as the Weibel-Palade bodies. When platelet or endothelial cells are activated by mediators such as thrombin, the membranes of the storage granules fuse with the plasma membrane, the soluble contents of the granules are released to

the external environment, and membrane bound P-selectin is presented within seconds on the cell surface, where it mediates adhesion of neutrophils, monocytes, and subsets of lymphocytes (McEver, in
5 Structure, Function, and Regulation of Molecules Involved in Leukocyte Adhesion, pages 135-150 (Lipsky et al., eds., Springer-Verlag, New York, 1993).

The expression of P-selectin, as observed by
10 immunohistochemistry (McEver et al., *J. Clin. Invest.*, 84, pages 92-99 (1989)) and Northern blot analysis (Johnston et al., *Cell*, 56, pages 1033-1044 (1989)), is restricted to megakaryocytes and endothelial cells. Under certain circumstances,
15 steady-state levels of mRNA and protein are increased by inflammatory mediators such as tumor necrosis factor and endotoxin (Sanders et al., *Blood*, 80, pages 795-800 (1992); Weller et al., *J. Biol. Chem.*, 267, pages 15176-15183 (1992); Hahne
20 et al., *J. Cell Biol.*, 121, pages 655-664 (1993)). Thus, an understanding of the molecular mechanisms that control transcription of the P-selectin gene may help clarify the mechanisms for gene expression in megakaryocytes and endothelial cells and for
25 regulation of leukocyte adhesion in response to tissue injury.

The promoters of several genes whose expression is restricted to endothelial cells or megakaryocytes have been partially characterized
30 (Lee et al., *J. Biol. Chem.*, 265, pages 10446-10450 (1990); Wilson et al., *Mol. Cell Biol.*, 10, pages 4854-4862 (1990); Ravid et al., *Mol. Cell Biol.*, 11, pages 6116-6127 (1991); Romeo et al., *Nature*, 344, pages 447-449 (1990); Uzan et al., *J. Biol. Chem.*, 266, pages 8932-8939 (1991)). The GATA
35 element, initially recognized in erythroid-specific promoters, plays an important role in expression of

some of these genes (Wilson et al., (1990), Romeo et al., (1990)). However, this element is not sufficient to mediate tissue-specific expression, as expression of the GATA-binding proteins does not directly correlate with expression of the genes containing GATA elements (Yamamoto et al., *Genes & Dev.*, 4, pages 1650-1662 (1990)). A functional ETS element has been identified in the megakaryocyte-specific gene for glycoprotein IIb (Prandini et al., *J. Biol. Chem.*, 267, pages 10370-10374 (1992); Lemarchandel et al., *Mol. Cell. Biol.*, 13, pages 668-676 (1993)), but this element is also found in genes expressed in other tissues (see, for example, Macleod et al., *Trends Biochem. Sci.*, 17, pages 251-256 (1992)).

It is an object of the present invention to characterize and provide DNA and RNA sequences of the 5' flanking region of the human P-selectin gene and to provide methods of using these sequences to specifically express P-selectin and other genes in endothelial cells and megakaryocytes.

It is another object of this invention to provide nucleic acid probes for screening for individuals with abnormal levels of P-selectin.

It is a further object of this invention to provide compositions and methods including the DNA or RNA sequences of the 5' flanking region of the human P-selectin gene for inhibiting or regulating P-selectin expression to control the inflammatory and hemostatic processes involving endothelial or megakaryocytic cells.

Summary of the Invention

The 5' flanking region of the P-selectin gene contains the regulatory sequences necessary for expression of P-selectin in endothelial and megakaryocytic cells. These regulatory sequences

are demonstrated to be useful to specifically express other genes in endothelial and megakaryotic cells, both *in vitro*, for example, in tissue culture, and *in vivo*, for example, in transgenic animals. In addition, these regulatory sequences can be used as probes to screen for individuals with abnormal levels of P-selectin and to make pharmaceutical compositions for the regulation or inhibition of P-selection expression in individuals having or predisposed to inflammation. Furthermore, sequences of the 5' flanking region of the P-selectin gene can be used to identify and isolate previously unknown proteins which are involved in regulation of gene expression.

15

Brief Description of the Drawings

Figure 1 is a schematic of the nucleotide (SEQ ID NO:3) and deduced amino acid (SEQ ID NO:4) sequence of endothelial cell P-selectin that was determined from a composite of four overlapping cDNAs: lambda GMPE1-lambda GMPE4. The relative positions of each of the cDNAs are shown by the solid arrows. The dotted arrows indicate regions found in some clones, but deleted in others. The numbering of the nucleotide sequence was arbitrarily started at the first base following the adapter oligonucleotide sequence of the most 5' clone. The translated amino acid sequence of the open reading frame is given in the single-letter code. The initiating methionine was assigned to the first in-frame ATG sequence that agreed with the consensus sequence for initiation of translation. The stop codon is shown by the asterisk. The thin underlines show the matching positions of amino acid sequences determined from the N-terminus and from 26 peptides of platelet P-selectin. The signal peptide corresponds to

positions -41 to -1. The putative transmembrane domain is heavily underlined. The cysteine residues are circled and potential asparagine-linked glycosylation sites (NXS/T) are shown by the dark circles. Two potential polyadenylation signals in the 3' untranslated region are underlined and overlined.

Figure 2 is the structure of the 5' flanking region of the P-selectin gene. The map shows the cloned region (scale in kb) with the positions of exons (numbered 1-3) and the bacteriophage and plasmid clones used. The region of the 5' flanking region sequenced is shown by the open box. All restriction sites for the following enzymes are shown on the map: B = *Bam*HI, E = *Eco*RI, Ev = *Eco*RV, H = *Hind*III, and X = *Xba*I.

Figure 3 illustrates the strategy to identify transcriptional start sites of the P-selectin gene and the primers used for primer extension studies and anchored polymerase chain reaction (PCR) and the probes used for RNase protection assays.

Figure 4 shows a summary of transcriptional start sites in the 5' flanking region (Seq ID No:5) of the P-selectin gene. Vertical arrowheads, vertical arrows, and horizontal arrows indicate, respectively, the positions of the transcriptional start sites determined by primer extension, RNase protection and anchored-PCR cloning. Each horizontal arrow represents an independent cDNA clone obtained by anchored PCR with sequence beginning at the indicated position between nucleotides (nt) 4768 and 4842 of SEQ ID NO. 5.

Figure 5 demonstrates transient expression analysis of P-selectin gene promoter activity. On the left are diagrams of the P-selectin promoter-luciferase fusion constructs. Vertical bars indicate the restriction sites used to make the

constructs. The PCR primers used to generate the shorter constructs are depicted with short arrows. The constructs are aligned with the 5' P-selectin gene sequences numbered relative to the

5 translational start site. Constructs p1339RLUC and p701RLUC have 5' flanking sequence oriented in the reverse direction. On the right is plotted the relative luciferase activity of bovine aortic endothelial cells (BAEC) transfected with each

10 construct. Activity is graphed as a percentage, with 100% equal to 24,000 light units per 25 μ g of cellular protein. The data represent the means \pm SD of at least three independent experiments. Duplicate transfections were performed in each

15 experiment; the variation between duplicates did not exceed 10% of the mean for the experiment.

Figure 6 demonstrates cell-specific expression of the 5' flanking sequence of the human P-selectin gene. The P-selectin-expressing BAEC and the

20 P-selectin-nonexpressing cell lines HeLa, 293, and COS-7 were transfected with the indicated constructs. Parallel transfections with the positive control plasmid pRSVLUC were simultaneously performed. Luciferase activity is

25 expressed as light units per 25 μ g of cellular protein. The data represent the means \pm SD of three independent experiments. Duplication transfections were performed in each experiment.

Figure 7 is the mutational analysis of the

30 GATA element. Three wild-type truncated chimeric constructs, and their three corresponding mutant constructs in which the TTATCA sequence was changed to TTTAGA, are depicted on the left of the figure. These constructs were transfected into BAEC, and

35 the luciferase activities were measured as percent relative luciferase activity. The data represent the means \pm SD of three independent experiments.

Duplicate transfections were performed in each experiment; the variation between duplicates did not exceed 5% of the mean for the experiment.

5 Figure 8 demonstrates the binding of nuclear proteins to the regulatory sequence encompassing the GATA element. The sequences of the upper strand oligonucleotides were used as probes and competitors. The P-selectin GATA and the nonconsensus GATA are from the indicated regions of
10 the 5' flanking sequence of the human P-selectin gene. The mutant oligonucleotide contains three nucleotide changes in the core GATA motif of the wild-type P-selectin sequence; the same changes were used in the mutant expression constructs
15 listed in Figure 7. The endothelin-1 GATA oligonucleotide corresponds to the functional GATA element in the human endothelin-1 promoter (Wilson et al., *Mol. Cell. Biol.*, 10, pages 4854-4862 (1990)).

20 Figure 9 shows five different recombinant gene constructs used to make transgenic mice. Each construct contains a different portion of the 5' flanking region of the P-selectin gene fused to the *lacZ* gene. Arrows indicate the orientation of the
25 portion of the 5' flanking region of the P-selectin gene fused to *lacZ*. Construct 2 is like Construct 1, except that the portion of the 5' flanking region of the P-selectin gene has been fused in the opposite orientation so that P-selectin gene
30 promoter function is directed away from *lacZ*.

Detailed Description of the Invention

I. Isolation, cloning and characterization of the gene encoding P-selectin and regulatory sequences associated with the P-selectin gene.

As used herein, unless otherwise specified, the term nucleic acid refers to DNA and the equivalent RNA.

Cloning of the gene for P-selectin was first reported by G.I. Johnston, R.G. Cook and R.P. McEver in Abstract 1238 Supplement II *Circulation*, 78(4) (October 1988). Oligonucleotides were prepared based on N-terminal amino acid sequencing of P-selectin peptides and used to screen a human endothelial cell cDNA library. A 3.0 Kilobase (kb) clone was isolated which encoded a protein of 727 amino acids. An N-terminal domain of 158 residues containing many cysteines, lysines, and tyrosines, is followed by an EGF-type repeating domain structure, and eight tandem repeats of 62 amino acids each, except for the sixth tandem repeat which has 70 amino acids. The repeats are homologous to those found in a family of proteins that include proteins regulating C3b and C4b, but are unique in having six conserved cysteines per repeat instead of the typical four. These are followed by a 24 amino acid transmembrane region and a 35 amino acid cytoplasmic tail.

As reported by Johnston, et al., in Abstract 1218, *Blood Suppl.* 72, 327a (November 1988), the gene for P-selectin has been localized to the long arm of chromosome 1, where genes for a number of C3b/C4b regulating proteins have been mapped.

As also reported, there appears to be at least two forms of the protein derived from alternative splicing of mRNA: a soluble form and a membrane or granule bound form. Both forms generally have a 186 bp insertion, encoding a ninth 62 amino acid

tandem repeat, between the sixth and seventh tandem repeats of the sequence. The soluble protein has a deletion that removes 40 amino acids including the transmembrane region.

5 The conclusion that P-selectin serves as a receptor for the adherence of leukocytes to activated endothelial cells and platelets was based on several observations. First, the rapid appearance of P-selectin on the surface of
10 endothelium stimulated with thrombin or histamine parallels the inducible adherence of neutrophils to endothelium stimulated with these agonists. In addition, platelets interact with neutrophils or monocytes only after activation with agonists such
15 as thrombin which cause redistribution of P-selectin to the cell surface; platelet agonists such as ADP which do not induce degranulation and surface expression of P-selectin do not cause platelets to adhere to leukocytes. Second, in
20 endothelium, P-selectin is concentrated in postcapillary venules, where E-selectin is concentrated. The concentration of both proteins in this region is important because postcapillary venules are the predominant sites for binding of
25 leukocytes to platelets prior to their migration across the endothelium into the tissues. Third, purified P-selectin coated on tissue culture microtiter wells mediates specific adherence of purified neutrophils to the wells. Fourth,
30 polyclonal and monoclonal antibodies to P-selectin block 60-90% of the adherence of neutrophils to cultured human umbilical vein endothelial cells stimulated with histamine. Fifth, the cDNA-derived amino acid sequence of P-selectin indicates that
35 its structure is remarkably similar to that of E-selectin, an endothelial cell protein known to bind

neutrophils. Sixth, leukocytes adhere to cells transfected with P-selectin cDNA.

The following methods were used for the production and characterization of P-selectin, antibodies thereto, and nucleotide sequences encoding P-selectin.

Protein Sequencing.

P-selectin was isolated and purified from human platelet membranes. On one occasion it was reduced under an atmosphere of nitrogen by the addition of dithiothreitol (20 mM, final concentration) and alkylated in the presence of iodoacetamide (Bray, et al., *Proc. Natl. Acad. Sci. USA*, 83, pages 1480-1484 (1986)). It was then digested with trypsin. The resultant peptides were isolated by two-step, reverse-phase, high performance liquid chromatography (HPLC) using previously described methods (Rosa, et al., *Blood*, 72:593-600 (1988)). On a second occasion, P-selectin was reduced and alkylated in the presence of 50 μ Ci [14 C]-iodoacetamide (Amersham) before unlabeled iodoacetamide was added. It was then gel-purified (Bray, et al., 1986) and electroeluted into 25 mM Tris, 192 mM glycine, pH 8.0, containing 0.1% Triton X-100 (Jacobs and Clad, *Anal. Biochem.*, 154, pages 583-589, 1986). One milligram of P-selectin was digested with endoglycosidase Glu-C (Boehringer-Mannheim Biochemicals) at a ratio of 1:10 w/w at 37°C. After 6 hr, an equal amount of protease was added and the mixture was incubated for a further 14 hr at 37°C. Peptides were isolated by reverse-phase HPLC as described by Rosa, et al., (1988), except that the initial separation on the C4 HPLC column was carried out using ammonium acetate buffer and the second separation on the C18 HPLC column was carried out using trifluoroacetic acid. Fractions containing

the purified peptides were concentrated to 50 μ l and kept frozen before sequencing. Amino acid sequences were determined from the N-terminus of the intact protein and from the peptides by using a gas-phase protein sequencer (Applied Biosystems Model 470A) (Rosa, et al., 1988). Cysteine residues were identified by their elution profile on the HPLC system used by the protein sequencer, and confirmed by measuring 14 C radioactivity in duplicate aliquots from each sequencing cycle.

cdNA Screening.

Based upon a portion of the amino acid sequence data, two pools of a 35-mer oligonucleotide probe, designed according to codon usage tables (Lathe, *J. Mol. Biol.*, 183:1-12 (1985), were synthesized. The complementary strand was used to allow hybridization to RNA by Northern blotting. Inosine was used in one position because the third base of a glycine codon showed no preferential nucleotide. The sequences of the pools were: POOL 1 (SEQ ID NO. 1):

5'-GC TGT CCA CTG ICC GAG GTT GTC ACA GCG CAC AAT-3'
 A A
 C T
 C

POOL 2 (SEQ ID NO. 2):

5'-GC TGT CCA CTG ICC GAG GTT GTC ACA TCT CAC AAT-3'
 A C
 C

On Northern blots, both oligonucleotide probes hybridized to a 3.6 kb transcript from poly(A)⁺ RNA isolated from CHRF-288 cells, a leukemia cell line with megakaryocyte-like properties (Witte, et al., *Cancer*, 58:238-244 (1986). Pool 2 probes hybridized more strongly and were therefore used to screen a cdNA library by standard procedures (Maniatis, et al., Molecular Cloning: A Laboratory

Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 1982). Approximately 1.4 million recombinant phage from an unamplified human endothelial cell lambda gt11 library (Ye, et al., *J. Biol. Chem.*, 262, pages 3718-3725 (1987) were plated out on *E. coli* Y1088 at a density of 200,000 plaques per 230-mm square plate of NZCYM agar. Duplicate nylon filters (Hybond-N, Amersham) were lifted, denatured, neutralized, and incubated at 42°C for 24 hr in prehybridization solution containing 5x standard saline citrate (SSC) [1x SSC is 150 mM NaCl, 15 mM sodium citrate], 5x Denhardt's solution [0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA], 0.2% SDS, and 200 µg/ml herring sperm DNA. The 35-mer oligonucleotide probe 2 was end-labeled with [gamma-³²P]ATP by 5'-polynucleotide kinase and was added to prehybridization solution to give a specific activity of 1 x 10⁶ cpm/ml. The filters were hybridized at 42°C overnight and the final washing conditions were 2x SSC, 0.1% SDS at 52°C. Positive plaques, identified by autoradiography of filters, were rescreened twice using the same probe and purified. The positive cDNA inserts were isolated from an agarose gel following digestion of phage DNA with *Sal*I or *Eco*RI. Either enzyme could be used because, during the library construction, cDNAs were ligated to adapter oligonucleotides containing a *Sal*I restriction site as well as an *Eco*RI site (Ye, et al., 1987). The inserts were subcloned into pIBI20 (IBI Biotechnologies, Inc.) for restriction mapping and DNA sequencing, and into M13mp18 (New England Biolabs) for DNA sequencing. Sequencing in M13mp18 was carried out by the dideoxy chain-termination procedure (Sanger, et al., *Proc. Natl. Acad. Sci. USA*, 74, pages 5463-5467 (1977)) using either modified T7 polymerase

(Sequenase from United States Biochemicals) or Klenow fragment of DNA polymerase (Bio-Rad Laboratories). Priming was performed with either the M13 universal primer or with 17-mer

5 oligonucleotides designed from cDNA sequence.

Double-stranded plasmid DNA, isolated by a standard alkaline-lysis mini-prep method (Maniatis, et al., 1982), was sequenced using the method described by Kraft, et al., *Biotechniques*, 6, pages 544-547

10 (1988). The plasmid templates were primed with either universal primer, reverse primer (International Biotechnologies, Inc.), or 17-mer oligonucleotides.

Isolation and Characterization of cDNA Clones.

15 Three clones, positive after tertiary screening, were plaque purified, and phage DNA was prepared. The inserts from the clones, designated lambdaGMPE1, lambdaGMPE2, and lambdaGMPE3, were subcloned into plasmids and sequenced. The DNA

20 sequences of all three clones contained long open reading frames which overlapped. The translated sequence of the longest clone, lambdaGMPE1, contained an amino acid sequence which matched the N-terminal amino acid sequence of intact platelet

25 P-selectin but which lacked an in-frame ATG, which encodes a methionine to initiate translation, 5' to this sequence.

To identify full-length cDNAs, 1.4 million recombinant phage of the now amplified endothelial-cell cDNA library were rescreened with a 1 kb *Sma*I

30 fragment from the 5' end of lambda GMPE1. Of the 55 positive clones identified, five were purified. DNA sequence from the 5' end of one of these new clones, designated lambdaGMPE4, matched the 5' end

35 of lambdaGMPE1, except that the first 88 bp were not found within the first 140 bp of lambdaGMPE1. Translation of the sequence of lambdaGMPE4 showed

that there was an in-frame ATG sequence beginning at nucleotide 39. The sequence of the 5' end of lambdaGMPE4 was also found in the other four clones obtained in the second screening of the cDNA library, suggesting that it was the correct sequence and that the first 140 bp of lambdaGMPE1 was a cloning artifact. As shown in Figure 1, sequence ID No.1 is a composite nucleotide sequence of the four clones, with 91% of the sequence derived from lambdaGMPE1. Sequence ID No. 2 is the predicted amino acid sequence.

The composite sequence predicts a 5' untranslated region of 38 bp, followed by an open reading frame of 2490 bp coding for a protein of 830 amino acids, then a 3' untranslated sequence of 614 bp including two potential polyadenylation signals of AATAAA and AATTAAA. The latter signal precedes a 12 bp sequence, then a poly(A)⁺ tail of 75 bp. The nucleotide sequence GxxATGG, surrounding the first in-frame ATG beginning at base 39, agrees with the consensus sequence for initiation of protein translation (Kozak, *Nucl. Acids Res.*, 12, pages 857-872 (1984)). Therefore the first amino acid was assigned to this codon.

When compared to the sequence of the other clones, there was a 186 bp segment deleted from lambda GMPE1, corresponding to nucleotides 1744 to 1929 (Sequence ID No. 1). A 120 bp deletion was also found in lambda GMPE2 and lambda GMPE3 (nucleotides 2326 to 2445). Eight single-base substitutions (confirmed by sequencing both strands of the cDNAs) were found in the first three clones. Three were silent substitutions, changing the third degenerate base of a codon. The other five produced conservative amino-acid changes.

Northern Blot Analysis.

Total RNA was prepared from the human megakaryocyte-like leukemia cell lines CHRF-288 (Witte, et al., *Cancer*, 58, pages 238-244 (1986)) and HEL (Papayannopoulou, et al., *J. Clin. Invest.*, 79, pages 859-866 (1982)), the myeloid cell line K562 (Lozzio and Lozzio, *Blood*, 45, pages 321-334 (1975)), human umbilical vein endothelial cells, the EA.hy 926 hybrid endothelial cell line (Edgell, et al., *Proc. Natl. Acad. Sci. USA*, 80, pages 3734-3737 (1983), human platelets, and the Daudi B-cell line (Klein, et al., *Cancer Res.*, 283, pages 1300-1310 (1969)) by an acid-guanidinium-phenol-chloroform procedure (Chomczynski and Sacchi, *Anal. Biochem.*, 162:156-159 (1987)). Both HEL cells and K562 cells were treated with Phorbol myristate acetate (PMA) for 48 hr. to induce differentiation before RNA was prepared. Poly(A)⁺ RNA was isolated from total RNA by oligo-dT cellulose chromatography (Davis, et al., Basic Methods in Molecular Biology (Elsevier, New York 1986)). Total or poly(A)⁺ RNA was electrophoresed on a 1% agarose gel containing formaldehyde, then transferred to a Hybond-N nylon membrane by standard procedures (Maniatis, et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor, NY, 1982)). The membrane was prehybridized in 5x SSC, 5x Denhardt's solution, 0.2% SDS, and 200 µg/ml herring sperm DNA for oligonucleotide probes, or in 5x Denhardt's solution, 50% formamide, 10% dextran sulfate, and 200 µg/ml herring sperm DNA for cDNA probes. Oligonucleotide probes were labeled by the procedure described above, and cDNA probes were random-labeled with a α -³²P dCTP using the Klenow fragment of DNA polymerase in a commercial kit (Boehringer-Mannheim Biochemicals). Probes were hybridized overnight at 42°C at a specific activity of at least 1 x 10⁶

cpm/ml. The filters to which the oligonucleotides were hybridized were washed with 2x SSC, 0.5% SDS for 20-min periods at increasing temperatures up to 52°C, whereas those used with the cDNA probes were washed with 0.2x SSC, 0.1% SDS at temperatures up to 60°C and were exposed to film (X-OMAT AR, Kodak) at -80°C. Molecular weight markers of lambda DNA (Boehringer-Mannheim Biochemicals), electrophoresed in parallel with the RNA samples, were visualized by including labeled lambda/HindIII DNA fragments (Bethesda Research Laboratories) [5×10^5 cpm/ml] in the hybridization solution.

Southern Blot Analysis.

Human placental genomic DNA (intact or digested with EcoRI, BamHI, and BamHI/HindIII) were obtained from Oncor. Intact DNA was also digested with PstI, TaqI, and XbaI. Ten μ g of each digested DNA was electrophoresed on a 1.5% agarose gel and transferred to a nylon membrane using a modification of the procedure of Reed and Mann, Nucl. Acids Res., 13, pages 7207-7221 (1985). Briefly, the gel was soaked in 0.2 M HCl for 10 minutes, rinsed four times in water, and transferred to a nylon membrane in 0.4 M NaOH buffer for 1 hr, then in 20x SSC overnight. The DNA was fixed to the membrane by exposure to UV light and hybridized with cDNA as described for the Northern blot. Lambda/HindIII fragments and ϕ X174/HaeIII fragments (Bethesda Research Laboratories) were used as standards and were visualized by including randomly labeled DNA fragments of lambda and ϕ X174 (5×10^5 cpm/ml) in the hybridization solution.

Computer Analysis.

DNA and protein sequence were analyzed using the Genetics Computer Group software package of the University of Wisconsin (Devereux, et al.,

Nucl. Acids Res., 12, pages 387-395 (1984)). The amino acid sequence of P-selectin was compared with the published sequences of other proteins contained in the National Biomedical Research Foundation (NBRF) database (Release 16.0; 3/88).

The 5' Flanking Region of the Human P-selectin Gene

The following methods were used for the isolation and characterization of the 5' flanking region of the P-selectin gene.

Cells.

Human HL-60 promyelocytic cells (ATCC No. CCL240), K562 erythroid cells (ATCC No. CCL 243), HEL erythroleukemia cells (ATCC No. TIB180), and Jurkat T-lymphocytes were maintained in RPMI 1640 supplemented with 10% fetal calf serum (FCS). Human HeLa epithelioid cells (ATCC No. CCL 2), 293 human embryonal kidney cells (ATCC No. CRL 1573), and COS-7 SV40-transformed African green monkey kidney cells (ATCC No. CRL 1651) were maintained in Dulbecco's Minimal Essential Medium (DMEM, high glucose) supplemented with 10% FCS. CHRF-288 human megakaryocytic cells (Witte et al., *Cancer*, 58, pages 251-256 (1986)) were maintained in Fisher's medium supplemented with 20% horse serum. Human umbilical vein endothelial cells (HUVEC) and bovine aortic endothelial cells (BAEC) were cultured as previously described (Moore et al., *J. Clin. Invest.*, 79, pages 124-130 (1987)).

Genomic cloning and Southern blot analysis.

A human genomic clone designated EMBL3-1 was obtained by screening a human genomic DNA library with a ³²P-labeled P-selectin cDNA as described above and by Johnston et al., *J. Biol. Chem.*, 265, pages 21381-21385 (1990). DNA restriction fragments derived from this clone were subcloned into the plasmid pIBI20 (IBI) for restriction enzyme mapping and DNA sequencing. All sequencing

was carried out by the chain-termination procedure (Sanger et al., *Proc. Natl. Acad. Sci. USA*, 74, pages 5463-5467 (1977)) using Sequenase (United States Biochemicals). Southern blot analysis of
5 human placenta genomic DNA was done as previously described (Johnston et al., *Cell*, 56, pages 1033-1044 (1989)) using a random-labeled probe corresponding to the 5' flanking region of the P-selectin gene from nucleotides (nt) 4405 to 4842
10 of SEQ ID NO. 5.

Determination of transcriptional start sites.

Poly(A)⁺ RNAs were prepared from cultured HUVEC, CHRF-288, HEL, and HL-60 cells by using the Fasttrack kit (Invitrogen). The poly(A)⁺ RNAs were
15 used for primer extension studies, RNase protection experiments, and anchored polymerase chain reaction (PCR) cloning. For primer extension analysis, a 27-mer primer was prepared with the sequence, 5'-TTCTGGTTTGTAGTTCAGAGATCAGG-3' (SEQ ID NO. 6).
20 The primer was 5' end-labeled with [γ -³²P]ATP (New England Nuclear, Inc) using T4 polynucleotide kinase (Pharmacia) and purified twice through a RNase free G-25 spin column (5'-3' Inc.). The specific activity of the labeled primer was 4 x 10⁶
25 cpm/pmol. The annealing of the primer and the extension reaction were performed as described by Mackman et al., *Proc. Natl. Acad. Sci. USA*, 87, pages 2254-2258 (1990) except that actinomycin D was not added. The reaction products were then
30 extracted with phenol/chloroform, precipitated by ethanol, and separated on a 6% sequencing gel along with a known DNA sequencing ladder.

To confirm the results obtained by primer extension analysis, RNase protection studies were
35 carried out with two different cRNA probes by the method of Cox et al., *Blood*, 77, pages 286-293 (1991). Briefly, two genomic DNA fragments

spanning the region from nt 4555 to 4842 and nt 4405 to 4842, respectively, of SEQ ID NO. 5 were amplified by PCR and subcloned into plasmid pIBI20 which contains a T7 promoter. The insert
5 nucleotide sequences were confirmed. The recombinant plasmids were linearized with an appropriate restriction enzyme and the cRNA probes were generated with T7 RNA polymerase (Promega). The cRNA probes were then purified on a 6%
10 sequencing gel. The linearized plasmids and cRNA probes were hybridized in 4 M guanidine thiocyanate and 25 mM EDTA (pH 6.0) at 42°C overnight, followed by treatment with RNase A and RNase T1 (Promega). Analysis of the protected products was performed as
15 described for the primer extension studies.

As a definitive approach to determine the transcriptional start sites, anchored PCR (Frohman et al., *Proc. Natl. Acad. Sci. USA*, 85, pages 8998-9002 (1988) was used to clone the 5' ends of a
20 number of P-selectin cDNAs. First-strand cDNA was synthesized from 2 µg of HEL cell mRNA with the cDNA Cyclekit (Invitrogen), containing the strong RNA denaturant methylmercuric hydroxide (MeHgOH), with a specific primer,
25 5'-GATGTATATCTCCACGCGAGTCCTCG-3' (SEQ ID NO. 7), which is complementary to nt 446-422 of SEQ ID NO. 3. After removing the excess primer with a Centricon 100 spin filter (Amicon), the 3' end of the first strand cDNA was tailed in a 30-µl volume
30 containing tailing buffer (Bethesda Research Laboratories), 1 mM dATP, and 15 units of terminal deoxynucleotidyl-transferase (Bethesda Research laboratories) for 10 min at 37°C, and then heated for 15 min at 65°C. The reaction mixture was
35 diluted to 200 µl, and 10-µl aliquots were used to synthesize the second strand cDNA with 10 pmol of the anchored-primer, 5'-GAATTCGAGCTCGGTACC

TTTTTTTTTTTTTTTTTT-3' (SEQ ID NO. 8), using 2.5 units of Taq DNA polymerase (Cetus) at 72°C for 7 min. The mixture was then subjected to PCR with two additional primers to improve specific

5 amplification and facilitate subcloning: an adaptor primer, 5'-GAATTCG AGCTCGGTACC-3' (SEQ ID NO. 9), which corresponded to the 5' end of the anchored primer and included restriction sites for EcoRI, SacI and KpnI, and a nested primer

10 5'-GTCGACTCTAGAATCAGCCCAGTTCTCAGC-3' (SEQ ID NO. 10), which was complementary to nucleotides 378-395 of the cDNA sequence and included XbaI and SalI sites. PCR was performed in a Perkin-Elmer/Cetus thermal cycler; the amplification profile involved

15 denaturation at 94°C for 1.5 min, primer annealing at 55°C for 2.5 min, and extension at 72°C for 1 min. The anchored PCR products were detected by Southern blot analysis with two ³²P-labeled internal oligonucleotides to verify the specificity of the

20 reaction. The largest products were then subcloned into pIBI20, and plasmid inserts from 21 individual colonies were sequenced.

Construction of chimeric luciferase expression vectors.

25 Plasmid p0LUC (originally designated p19LUC) and pRSVLUC (DeWet et al., *Mol. Cell. Biol.*, 7, pages 725-737 (1987)) were gifts from Dr. Donald Helinski (University of California, San Diego). The parental DNA for the creation of deletion

30 mutants was a 5-kb HindIII fragment inserted into pIBI20 (pGHindIII, Figure 2) that contained the 5' flanking region, first exon, and part of the first intron of the P-selectin gene. Plasmid p1339LUC in the correct orientation and p1339RLUC in reverse

35 orientation were constructed by inserting the 1.3 kb P-selectin 5' flanking region excised by HinfI from pGHindIII into the SmaI site of p0LUC. Plasmids p701LUC, p701RLUC, p459LUC, p309LUC,

p249LUC, p197LUC, p147LUC, p128LUC, p100LUC, and p80LUC were constructed by ligation of the respective DNA segments generated by PCR from pGHindIII into the *SmaI* site of p0LUC. Plasmid p4863LUC was constructed in three steps: 1) ligation into the *EcoRV* and *EcoRI* sites of pBluescript II KS (Stratagene, La Jolla, CA) of the fragment from nt 4596 to 4851 of SEQ ID NO. 5 released from p309LUC with *EcoRV* and *EcoRI*; 2) insertion between the *HindIII* and *EcoRV* sites of the above construct of a fragment from nt 1 to 4596 of SEQ ID NO. 5 released from pGHindIII with *HindIII* and *EcoRV*; and 3) removal by *HindIII* and *SmaI* of the sequence from nt 1 to 4851 of SEQ ID NO. 5 from the above construct followed by ligation into the *HindIII* and *SmaI* sites of p0LUC. Plasmid pm309LUC, pm249LUC, and pm197LUC, each of which contained three identical mutations in the TTATCA element, were constructed by an overlap extension PCR protocol (Disdier et al., *Mol. Biol. Cell*, 3, pages 309-321 (1992)). Briefly, two separate PCR products, one for each half of the hybrid product, were generated with either an antisense or sense mutated GATA oligonucleotide (described below for the gel shift assay) and one outside primer. The two products were gel purified and mixed. A second PCR was then performed using the two outside primers. The PCR product was blunt-ligated into the *SmaI* site of p0LUC. All the constructs were verified by sequencing the inserts and flanking sites in the plasmid.

Molecular cloning of the 5' flanking region of the P-selectin gene.

The genomic clone EMBL3-1 encoding the 5' untranslated region of P-selectin cDNA was obtained, as described above, by screening a genomic DNA library with a ³²P-labeled P-selectin cDNA (Johnston et al., *J. Biol. Chem.*, 265, pages

21381-21385 (1990)). A 5 kb HindIII fragment encoding the 5-untranslated region of the P-selectin gene, derived from genomic clone EMBL3-1, was subcloned into pIBI20, analyzed by restriction mapping (Figure 2), and sequenced on both strands. Southern blot analysis of human genomic DNA with a labeled DNA fragment derived from this clone revealed that restriction fragments were identical in size to those in the clone, suggesting that there was no DNA rearrangement during cloning.

Transcriptional start sites in the 5' flanking region.

To define the transcriptional start sites for the P-selectin gene, three assays were used, as shown in Figure 3.

To map transcriptional start sites by primer extension, 10 μ g of poly (A⁺) RNA from HEL cells, CHRF-288 cells, or HUVEC, or 10 μ g of yeast tRNA was hybridized with a 5'-end-labeled oligonucleotide primer. After incubation with reverse transcriptase, primer-extended products were analyzed on a 6% sequencing gel. A sequence ladder of the plasmid pIBI20 was used as size markers (lanes G, A, T, and C). At least 12 extension products were seen from nt 4769 to 4839 of SEQ ID NO. 5 relative to the ATG codon initiating translation of mRNA. Extension products of the same size were produced by mRNA from HUVEC and from the megakaryocytic cell lines CHRF-288 and HEL, but not by control tRNA.

Similar results were obtained by RNase protection assay using two independent cRNA probes surrounding the first exon. The two cRNA probes produced the same protected band patterns, most of which corresponded in size to the primer extension products. Ten micrograms of poly (A⁺) RNA from HEL cells, HL-60 cells, or yeast tRNA were hybridized with each of the two different cRNA probes. After

treatment with RNase, the protected products were run on a 6% sequencing gel. RNase-protected bands corresponding to the smallest primer extension products were not observed due to the short cRNA probes used. However, these short primer extension products were consistently observed, indicating that they reflected alternative transcriptional start sites rather than premature stops during reverse transcription.

To rule out generation of multiple bands through alternative splicing of pre-mRNAs, anchored PCR was performed to clone the 5' ends of cDNAs from HEL cell mRNA. Twenty-one clones were sequenced. The sequences of the 5' ends of these cDNA clones matched the genomic sequence and corresponded in length to those predicted from the primer extension and RNase protection products.

The most abundant clones began at 4786, 4814, and 4832 (four clones each) of SEQ ID NO. 5, which matched the sizes of the most prominent products determined by RNase protection and/or primer extension. These data, summarized in Figure 4, indicate that transcription of the P-selectin gene is initiated at multiple identical start sites in both endothelial and megakaryocytic cells.

Structural features of the 5' flanking region.

The sequence of 4866 bp of 5' flanking region concluding with the ATG at the end of the exon 1 is shown in SEQ. ID NO:3. No canonical TATA and CCAAT boxes were found in the P-selectin flanking sequence. The nucleotide sequence was not GC rich and lacked a GC box (the binding site for transcription factor Sp1) that is found in many "housekeeping" genes without TATA boxes (Reynolds et al., *Cell*, 38, pages 275-285 (1984)). It also lacked an "initiator" sequence which is required for accurate initiation of transcription in some

TATA-less genes (Smale et al., *Cell*, 57, pages 103-113 (1989)). A number of potential regulatory elements were present, including two sites at 4707-4711 and 4105-4110 recognized by the GATA family of zinc finger transcription factors (Yamamoto et al., *Genes & Dev.*, 4, pages 1650-1662 (1990); Orkin, *Cell*, 63, pages 665-672 (1990), a CACCC (GGGTG) element at 4648-4652 frequently seen in the promoters of erythroid-expressed genes (Frampton et al., *Mol. Cell. Biol.*, 10, pages 3838-3842 (1990); Schule et al., *Nature*, 332, pages 87-90 (1988), a GGGGGTGACCCC (4646-4657 of SEQ ID No. 5) overlapping with the CACCC element that is similar to the binding sites recognized by the subunit NFKB1 (p50) of the NF- κ B/rel family (Blank et al., *Trends Biochem Sci.*, 17, pages 135-140 (1992)) and by a zinc finger nuclear protein family that includes MBP-1 and MBP-2, 10 elements beginning at 4761, 4727, 4641, 4645, 4505, 4471, 4457, 4212, 4206, and 3732 of SEQ ID NO. 5, which contain a GGAAG/A SEQ core sequence that is similar to the binding site for the ETS class of oncoproteins (Karim et al., *Genes & Dev.*, 4, pages 1451-1453 (1990)), and a TCTGGAATGTG (4747-4757 of SEQ ID NO. 5) that is related to the GT-IIC element of the SV40 enhancer (Burglin, *Cell*, 66, pages 11-12 (1991)).

II. Cell Specific Expression under the control of the 5' P Selectin Regulatory Sequence.

30 Transfection and Luciferase assay.

Plasmids used for transfections were purified by cesium chloride banding. At least two different batches of plasmids for each construct were tested for the transfections. Cells were plated on a 100 mm petri dish at a density adjusted so that they reached 70-80% confluence prior to transfection. Equal volumes of 60 μ g of test plasmid and 50 μ g of lipofectin reagent (BRL), each diluted in 2.5 ml of

OptiMEM medium (BRL), were incubated for 20 min and the resulting transfection mixture was then added to the cells. After an 8 to 12 h incubation at 37°C, the transfection medium was replaced by
5 complete medium for an additional 36 h and the cells were then harvested for luciferase assays in a total volume of 120 μ l (DeWet et al., *Mol. Cell. Biol.*, 7, pages 725-727 (1987)). Briefly, following lysis and removal of the cell debris by
10 centrifugation, 20 μ l of total cellular extracts were used for each measurement for luciferase activity. The luciferase activity for each transfection was measured three times with a Monolight 2001 luminometer. The luciferase
15 activities were normalized to the amount of protein in cellular extracts as measured by the Bradford reagent (Bio-Rad).

Preparation of cell extracts and gel shift assay.

20 HEL, CHRF-288, K562, Jurkat, Hela, and BAEC cell nuclear extracts were prepared as described by Dignam et al., *Nucl. Acids Res.*, 11, pages 1475-1489 (1983). Extracts from HUVEC were prepared at miniscale as described by Schreiber et al., *Nucl.*
25 *Acids Res.*, 17, pages 6419 (1989). COS-7 cells were transfected with a plasmid encoding human GATA-2 (Dorfman et al., *J. Biol. Chem.*, 267, pages 1279-1285 (1992)), a gift from Dr. Stuart Orkin (Harvard Medical School, Cambridge, MA), or mock-
30 transfected with the plasmid pIBI20. Extracts from GATA-2-transfected or mock-transfected COS-7 cells were prepared as described in Tsai et al., *Nature*, 339, pages 446-451 (1989). A standard gel shift assay (20 μ l) contained 5,000-10,000 cpm of labeled
35 oligonucleotide, 2.5 μ g of poly(dI·dC), 60 mM KCl, 4 mM Tris (pH 7.5), 12 mM Hepes, 1 mM dithiothreitol, 1 mM EDTA, 10 μ g bovine serum

albumin, and 3 μ l (6 μ g) of cell extracts. Gels of 4-6% acrylamide (19:1 acrylamide/N,N'-methylenebis-acrylamide w:w) were run in 0.25 x TBE buffer (1x TBE = 0.089 M Tris, 0.089 M boric acid, and 0.002 M EDTA) at 150 V and then dried prior to autoradiography. For competition experiments, unlabeled competitor duplex DNA was added to the reaction mixture before the addition of labeled probe.

10 Transgenic Mice.

The *lacZ* gene was excised from pCH110 (Pharmacia-LKB) by digestion with *Hind*III and *Apa*I and ligated into the phagemid, pBluescript SK+ (Stratagene), pre-digested with the same enzymes. Constructs 1-3 were prepared by removing the 5' flanking sequences of the P-selectin gene from, respectively, p1339LUC, p1339RLUC, and p701LUC (see above), by digestion with *Bam*HI and *Xba*I and inserting the sequences into pBluescript at the corresponding sites such that the 5' flanking sequence was separated from *lacZ* by only a few base pairs of sequence in the polylinker region of the plasmid. Constructs 4 and 5 were prepared by excising the 5' flanking sequences from p459LUC and p309LUC with *Hind*III and *Eco*RI and inserting the sequences into the same *lacZ*-Bluescript vector.

Each of the five plasmids was purified on cesium chloride gradients. The insert containing the P-selectin 5' flanking region fused to *lacZ* was released from the plasmid by digestion with *Bam*HI and *Xba*I. After purification from agarose gels, the DNA insert was microinjected into the pronuclei of oocytes obtained from mating mice. The microinjected oocytes were then implanted into the infundibulum of the Fallopian tubes of pseudopregnant mice using standard techniques (Hogan et al. in Manipulating the Mouse Embryo. A

Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1986) (incorporated herein by reference). Incorporation of the transgene into offspring was determined by PCR analysis of tail-
5 vein DNA, using primers specific for the 5' flanking sequence and the *lacZ* sequence (Chen and Evans, *Biotechniques*, 8, 32-33 (1990)). Expression of the transgene in tissues of founder mice or their offspring was determined by a cytochemical
10 staining procedure for β -galactosidase (Sanes et al., *EMBO J.*, 5, pages 3133-3142 (1986)).

Transient expression analysis of the 5' flanking region.

To test whether the 5' flanking region of the
15 P-selectin gene had promoter activity, chimeric constructs were prepared in which serially deleted fragments of 5' flanking sequence were inserted before a promoterless luciferase gene in the plasmid p0LUC (Figure 5). Luciferase expression
20 was measured following transfection of the constructs into BAEC. Constructs p4863LUC, p1339LUC, p701LUC, p459LUC, p309LUC, and p249LUC promoted similar levels of luciferase activity that were significantly higher than the background
25 amounts in p0LUC-transfected cells. Serial decreases in expression were observed following transfection with p197LUC and with p147LUC and p128LUC. Only background expression was observed following transfection with p100LUC and p80LUC.
30 These data indicate that the sequences responsible for most of the promoter activity are located between 4615 and 4861 of SEQ ID NO. 5. These data also indicate that there are at least three positive regulatory domains between 4615 and 4764
35 of SEQ ID NO. 5 (for example, compare p249LUC, p197LUC, p128LUC, and p100LUC). The results also show that some of the positive elements in the longer constructs were position dependent, as

p1339RLUC and p701RLUC, which contained flanking sequence in reverse orientation, expressed no more luciferase in BAEC than p0LUC.

To determine whether the constructs mediated tissue-specific expression, they were transfected into COS-7, 293, and Hela cells, which do not normally synthesize P-selectin, as shown by Figure 6. In contrast to their effects in BAEC, constructs p1339LUC, p701LUC, p459LUC, and p309LUC had only basal promoter activity in these cells, although the basal levels did exceed the background activity of mock-transfected cells or cells transfected with p0LUC. Parallel transfections with RSVLUC, a plasmid containing luciferase driven by the Rous sarcoma virus promoter, resulted in high levels of expression, indicating that the cells could be transfected. These data indicate that the flanking sequence from nt 4555 to 4851 of SEQ ID NO. 5 includes elements that can direct the regulated expression of a gene in endothelial cells.

The GATA element at 4706 of SEQ ID NO. 5 is required for optimal function of the P-selectin promoter.

Deletion of the sequence between nt 4667 and 4717 of SEQ ID NO. 5 significantly reduced luciferase expression in BAEC, as shown by Figure 5, indicating the presence of a positive regulatory element(s) in this region. To determine whether the GATA (TTATCA) element at 4706 of SEQ ID NO. 5 functioned as such a positive element, the wild-type sequence TTATCA was mutated to TTTAGA in the three constructs p309LUC, p249LUC, and p197LUC, as shown by Figure 6. When the mutant constructs were transfected into BAEC, luciferase expression in each case was reduced to the level of p147LUC, which was only 20% of that produced by p309LUC. These results indicate that the GATA element is

essential for optimal transcription of the P-selectin gene, perhaps through interactions with other regulatory sequences located between nt 4555 to 4666 of SEQ ID NO. 5.

5 Gene Expression in Megakaryocytes of Transgenic Mice Containing the P-selectin Promoter.

10 The use of the 5' flanking region of the P-selectin gene to direct the expression of a heterologous gene in megakaryocytes was demonstrated by analysis of transgenic mice carrying portions of the 5' flanking region of the P-selectin gene fused to the bacterial *lacZ* gene.

15 Five constructs were made in which DNA, having the sequence of nt 3525 to 4851 (or the same sequence inserted in the opposite orientation), 4163 to 4851, 4405 to 4851, or 4555 to 4851 of SEQ ID NO. 5, was fused to the 5' coding region of the *lacZ* gene, as described in Figure 9. Each
20 construct was then cloned and used to prepare transgenic mice as described above. Offspring carrying the transgenes for each of the five constructs were produced from founders. An analysis of bone marrow cells from mice carrying
25 the construct having the sequence of nt 4163 to 4851 of SEQ ID NO. 5 fused to *lacZ* indicated that the transgene was expressed by megakaryocytes but not by other bone marrow cells.

30 The above results clearly indicate that the sequences of the 5' flanking region of the P-selectin gene can specifically direct the regulated expression of a gene in endothelial and megakaryocytic cells. Accordingly, a gene can be specifically expressed in endothelial cells or
35 megakaryocytes by ligating, or otherwise fusing (for example, by PCR), the 5' end of the coding sequence of the gene to the 3' end of a DNA sequence consisting essentially of nucleotides 1 to

4863 of SEQ ID NO. 5, or one or more of the transcriptional regulatory sequences of SEQ ID NO. 5, to yield a recombinant gene construct, and transfecting, or otherwise inserting using methods known to those skilled in the art (for example, by transgenic methods, microinjection, liposome fusion) the recombinant gene construct into endothelial cells or megakaryocytes.

It is likely that some modifications in the sequence of the 5' flanking region can be introduced into the cells without alteration in function. For example, the 5' flanking sequences of a given gene in different species may be slightly different; the differences are usually in regions not critical for function and therefore not conserved among species. It is believed that the 5' flanking sequences of the P-selectin gene in other species will also be functional in humans; this prediction is supported by the observed function of the human P-selectin flanking sequence in transgenic mice (see above).

III. The 5'-P Selectin Regulatory Sequence can be used to isolate Novel Proteins.

The function of the GATA element correlates with its ability to bind nuclear proteins.

To determine whether the GATA element bound nuclear proteins, a 40-bp double-stranded oligonucleotide probe encompassing this sequence was synthesized, as shown in Figure 8. The ³²P-labeled probe was incubated with nuclear extracts from various cell lines in the presence of poly (dI·dC) as a competitor for nonspecific DNA-protein interactions. The resultant complexes were separated by electrophoresis on a nondenaturing polyacrylamide gel. For example, two distinct complexes (labeled A and B, where A has the slower mobility in the gel) were observed on gels when K562 and HEL cell nuclear extracts were incubated

with end-labeled P-selectin GATA oligonucleotide. Complex formation was sequence specific, as it was prevented by addition of a 100-fold molar excess of the unlabeled GATA oligonucleotide, but not by a
5 100-fold excess of an oligonucleotide encoding a nonconsensus GATA sequence located further upstream in the P-selectin 5' flanking region. Similar complexes were formed using nuclear extracts from CHRF-288, BAEC, HUVEC, and Jurkat cells, although
10 sometimes one of the complexes was only present in relatively small amounts. Two minor complexes were also observed in the gels, but these appeared to represent proteolytic degradation products as they were noted only in nuclear extracts stored for
15 prolonged intervals.

To determine whether the GATA element was required to form the observed complexes in the gel shift assays, competition gel shift assays were carried out on HEL cell nuclear extracts with an
20 oligonucleotide encoding the GATA motif from the human endothelin-1 gene promoter and the results compared to a competition gel shift assay carried out with the oligonucleotide encoding the P-selectin GATA motif, as shown by Figure 8. The
25 results indicated that the unlabeled human endothelin-1 GATA oligonucleotide probe prevented formation of complex B, but not complex A, by the ³²P-labeled P-selectin probe containing the GATA consensus sequence. The labeled endothelin-1 probe
30 formed a complex with a mobility similar, although not identical, to complex B. Formation of this complex was prevented by addition of either the unlabeled endothelin-1 probe or the P-selectin probe.

35 These data indicate that complex B represents the interaction of a member of the GATA protein

family with the GATA consensus sequence in the P-selectin promoter.

To test whether the core GATA sequence was required for binding of nuclear proteins, a mutant oligonucleotide was synthesized (Figure 8) in which the core sequence TTATCA was converted to TTTAGA, the same changes made in the mutant constructs shown in Figure 7. HEL cell and BAEC nuclear extracts were incubated with end-labeled wild-type or mutant P-selectin GATA probe in the absence or the presence of the indicated unlabeled competitor. The results showed that a 100-fold molar excess of the unlabeled mutant probe prevented formation of complex A, but not complex B, when the labeled P-selectin GATA oligonucleotide was incubated with nuclear extracts from HEL and BAEC. Furthermore, the labeled mutant probe formed complex A, but not complex B. These data indicate that the core GATA sequence is required for formation of complex B, but not complex A.

To confirm that the consensus GATA element in the P-selectin promoter bound to a member of the GATA protein family, gel shift assays were performed with extracts from COS-7 cells transfected with an expression plasmid encoding human GATA-2. Labeled P-selectin probe was incubated with extracts from mock-transfected COS-7 cells (mock) or with COS-7 cells transfected with an expression plasmid encoding human GATA-2 (hGATA-2) in the presence or absence of unlabeled P-selectin GATA, unlabeled human endothelin-1 GATA, or nonconsensus GATA oligonucleotides as competitors.

The hGATA-2-transfected COS-7 extracts, but not those from mock-transfected cells, formed a DNA-protein complex with the ³²P-labeled P-selectin GATA probe. Formation of this complex was

inhibited by addition of the unlabeled endothelin-1 GATA oligonucleotide as well as by the unlabeled P-selectin probe. These results indicate that the P-selectin GATA probe binds a member(s) of the GATA protein family.

Other nuclear protein binding sites.

The luciferase expression studies described above indicated that the sequences responsible for most of the P-selectin promoter activity in endothelial cells are located in the sequence between nt 4615 and 4851 of SEQ ID NO. 5 and that at least three positive regulatory sequences are located between nt 4615 and 4764 of SEQ ID NO. 5. In addition to these sites, gel shift studies also indicated the existence of at least three regulatory sites in a 52 base pair portion of the 5' flanking region of the P-selectin gene having the sequence from nt 4615 to 4666 of SEQ ID NO. 5. This conclusion was obtained by gel shift studies of four complexes that were first observed to form between nuclear protein extracts from several cell types and a double-stranded ³²P-labeled oligonucleotide corresponding to the sequence from nt 4632 to 4672 of SEQ ID NO. 5. Starting with the complex with slowest mobility in the gels, these complexes were designated as I, then a closely-spaced doublet IIa and IIb, then III. Extracts from some cell types formed some, but not all, of the complexes. For example, complex I was not formed by extracts of HUVECs.

Complex I was also formed by mixing nuclear extracts with an oligonucleotide having the sequence of nt 4650 to 4669 of SEQ ID NO. 5. This sequence is not related to those of known DNA regulatory elements. Complex I was formed with nuclear extracts from BAECs, but complex formation was prevented when extracts were prepared from the

same cells following stimulation with phorbol myristate acetate. These results indicate that the sequence of nt 4650 to 4669 of SEQ ID NO. 5 is bound by previously undescribed regulatory protein(s).

The complexes corresponding to the IIa and IIb doublet (referred to collectively as complex II for simplicity) represent interactions of the DNA with members of the NF κ B family, a group of homodimeric or heterodimeric DNA-binding proteins that help regulate expression of many genes (Blank et al., *Trends Biochem. Sci.*, 17, pages 135-140 (1992)). Complex II was formed not only when nuclear extracts were mixed with the oligonucleotide having the sequence of nt 4632 to 4672 of SEQ ID NO. 5, but also when mixed with a oligonucleotide having the shorter sequence of nt 4642 to 4664 of SEQ ID NO. 5. Formation of complex II was inhibited by an unlabeled oligonucleotide having the sequence CGGCTGGGGATTCCCATCT (SEQ ID NO. 11), which contains the NF κ B element of the mouse *H-2K^b* class I major histocompatibility (MHC) promoter. Complex formation was also inhibited by a combination of antisera to NF κ B1 and NF κ B2 subunits, two of the subunits found in certain dimeric NF-KB proteins, but not by preimmune sera. Furthermore, the labeled oligonucleotides bound to purified recombinant homodimers of NF κ B1 and NF κ B2, but not to homodimers of recombinant Rel A, another subunit found in some dimeric NF-KB proteins, or to heterodimers that contain the Rel A subunit in cell extracts. Methylation interference studies indicated that the GGGG sequence in the sense strand (nt 4646 to 4650 of SEQ ID NO. 5) and the GGGG in the antisense strand (nt 4654 to 4657 of SEQ ID No. 5) participated in direct contacts with NF κ B1 and NF κ B2 homodimers. Furthermore, a mutant

oligonucleotide spanning the 4642 to 4664 sequence, in which the CCCC sequence at 4654 to 4657 was altered to ATAG, failed to interact with NFKB1 or NFKB2 in gel shift assays. These results indicate
5 that the sequences recognized by NFKB1 and NFKB2 in the 4642 to 4664 region are consistent with known recognition features for members of the NF- κ B family.

Formation of complex III required the inverted
10 repeat sequence of nt 4635 to 4646 of SEQ ID NO. 5. Simultaneous mutations in both halves of the inverted repeat changing the sequence from CTTCCATGGAAG (nt 4635 to 4646 of SEQ ID NO. 5) to GTTGGTTCCAAG (SEQ ID No. 12), GTTGGTTTAAAG (SEQ ID
15 No. 13), or CTTCCATCCAAG (SEQ ID No. 14), abolished complex formation. An oligonucleotide having the sequence from nt 4626 to 4650 of SEQ ID NO. 5 also formed complex III. The sequence requirements for the formation of complex III indicate that one or
20 more members of the ETS class of transcription factors may bind to this sequence of the 5' flanking region of the P-selectin gene. Complex III was formed by extracts from all cells tested (HEL, CHRF-288, K562, Jurkat, HL-60, HUVEC, BAEC,
25 EAhy.926, and Hela), indicating that the transcription factor(s) interacting with sequence of 4626 to 4650 of SEQ ID No. 5 is widely expressed. Of the known ETS proteins, ets-2 and GABP are the most widely distributed (Macleod et
30 al., *Trends Biochem. Sci.*, 17, pages 251-256 (1992)). However, oligonucleotides encoding known recognition sites for these proteins, that is, TCGAGCAGGAAGTGACGTCGA (SEQ ID NO. 15) or GGCCAAACCGGAAGCATGTG (SEQ ID NO. 16) for ets-2 and
35 AGCTTGCGGAACGGAAGCGGAAACCGCCGGATCG (SEQ ID NO. 17) for GABP, did not prevent formation of complex III with the labeled -238 to -214 oligonucleotide,

indicating that ets-2 and GABP are not interacting with this region in the 5' flanking region of the P-selectin gene. These results indicate that the portion of the 5' flanking region of the P-selectin gene defined by nt 4635 to 4646 of SEQ ID NO. 5 is bound by previously undescribed protein(s). Such proteins may be unidentified members of the ETS family or of other families of transcription factors.

10 Recently a pathway has been elucidated that connects signaling at the cell surface directly to gene activation (reviewed by Darnell, et al., *Science*, 264, pages 1415-1421 (1994); Ihle, et al., *Trends Biochem. Sci.*, 19, pages 222-227 (1994);

15 Sato and Miyajima, *Curr. Opin. Cell Biol.*, 6, pages 174-179 (1994)). This pathway is used by the interferons and by many cytokines and growth factors, including IL-3, IL-4, IL-6, oncostatin M, and epidermal growth factor. In general, binding

20 of ligand induces dimerization or oligomerization of its receptor that allows association with JAK kinases, which phosphorylate a tyrosine residue in a group of transcription factors known as the STATS (signal transducers and activators of

25 transcription). The phosphorylated STATS then dimerize and migrate to the nucleus, where they bind to specific DNA elements, alone or in combination with other transcription factors, resulting in transcriptional activation. Cytokines

30 IL-3, IL-4, IL-6, and oncostatin M induce increased levels of P-selectin mRNA in cultured human umbilical vein endothelial cells or in bovine aortic endothelial cells, as measured by Northern blotting. Transcript levels begin to increase at 7

35 hours and are even higher at 24 hours following stimulation with each cytokine. A review of the sequence of the 5' flanking region of the human P-

selectin gene revealed at least four elements that shared sequence similarity to consensus binding sites for members of the STAT protein family: nt 4453 to 4461, nt 4636 to 4645, nt 4722 to 4731, and nt 4745 to 4753 of SEQ ID NO. 5. A double-stranded oligonucleotide encompassing the first putative element, consisting of the sequence from nt 4446 to 4469 of SEQ ID NO. 5, formed inducible complexes with nuclear proteins from several cell lines stimulated for 30 min with interferon- γ or IL-6. Formation of these complexes was inhibited by addition of an unlabeled oligonucleotide containing the hSIE sequence, an element known to bind with high affinities to stat1 homodimers, stat3 homodimers, and stat1-3 heterodimers (Zhong, et al., *Science*, 264, pages 95-98 (1994)). Antibody supershift experiments confirmed that two of the complexes formed by the SEQ 18 oligonucleotide contained stat1, and the mobility of another complex, elicited primarily by IL-6, suggests that it represents stat3 homodimers. The SEQ 18 element formed two additional complexes with nuclear extracts from the human megakaryocytic cell line, CHRF-288; one of these complexes was inducible by treatment with IL-4 for 16 hours. Formation of the latter two complexes, which may represent binding to novel STAT proteins, was not competed with the hSIE oligonucleotide. Collectively, these data indicate that several different cytokines can induce increased steady-state levels of P-selectin transcripts, and that one potential mechanism for these inducible increases may be binding of phosphorylated STAT proteins to elements in the 5' flanking region of the human P-selectin gene.

The gel-shift assays clearly indicate that sequences defined by nt 4650 to 4669, 4635 to 4646, and 4642 to 4664 of SEQ ID NO. 5, identify distinct

domains within in the 5' flanking region of the P-selectin gene which play a significant role in the regulation of the expression of the P-selectin gene in endothelial and megakaryocytic cells. The gel-shift assays also indicate the existence of previously unknown regulatory proteins that bind these distinct domains of the 5' flanking region of the P-selectin gene. In particular, sequences defined by nt 4650 to 4669 and nt 4635 to 4646 of Seq ID No. 5 were sufficient to form two distinct complexes, i.e., complex I and complex III, respectively. Unlike the sequence defined by nt 4642 to 4664 of SEQ ID NO. 5, which has recognition features for proteins of the NFkB regulatory protein family, the sequences required for complex I have no obvious homology to sequences recognized by any known regulatory protein family. The sequences required to form complex III may allow binding of an unknown member of the ETS family or binding of a previously uncharacterized protein in some other class of transcription factors. The nucleotide sequence defined by nt 4446 to 4469 of SEQ ID NO. 5 appears to bind two known STAT family members, stat1 and stat3, and may bind to additional novel members of this family. Elements encompassing nt 4636 to 4645, nt 4722 to 4731, and nt 4745 to 4753 of SEQ ID NO. 5 are also candidate binding sites for known or novel STAT proteins.

Accordingly, the sequences of the 5' flanking region of the P-selectin gene defined by nt 4650 to 4669 and 4635 to 4646 of SEQ ID NO. 5 are recognized and bound by regulatory proteins with previously undescribed features and are useful for the identification and isolation of such regulatory proteins. Sequences encompassing nt 4446 to 4469, nt 4636 to 4645, nt 4722 to 4731, and nt 4745 to 4753 of SEQ ID NO. 5 may also bind to novel members

of the STAT family of transcription factors and could be used for the identification and isolation of such proteins. For example, such sequences could be attached to resins for use in the
5 isolation of unknown DNA binding proteins by affinity chromatography. As another example, such sequences could be labeled using standard methodology and used to screen for clones expressing previously unknown regulatory proteins,
10 or functional peptides thereof, in cDNA expression libraries made from mRNA from endothelial cells, megakaryocytic cells, or other cells. Of course, any other consecutive sequence of SEQ ID NO. 5 that has been shown to define a regulatory site in the
15 5' flanking region of the P-selectin gene could similarly be used in such methods to isolate the particular regulatory protein(s) that bind that sequence using techniques described herein.

IV. Diagnostic Methods

20 The luciferase expression studies, the gel shift studies, and the lacZ transgene experiments, above, clearly demonstrate that the integrity of the 5' flanking region of the P-selectin gene is critical for gene expression in endothelial and
25 megakaryocytic cells. A disruption, deletion or other mutation in the sequence of nucleotides in this region can reduce or otherwise alter expression of the P-selectin gene, or heterologous gene properly ligated to this 5' flanking region.
30 Accordingly, the DNA sequences of the 5' flanking region of the P-selectin gene can be used as hybridization probes to detect or screen for mutations in the 5' flanking region of the P-selectin gene of individuals with abnormal levels
35 of expression of P-selectin, particularly those with elevated expression which have clinical symptoms of inflammation. In addition, DNA

molecules including the DNA sequences of the 5' flanking region of the P-selectin gene can be transcribed to yield the corresponding RNA molecules, if in the judgment of the skilled practitioner it is more desirable to use RNA probes instead of DNA probes.

Calculations and empirical work by Lathe and others, Lathe, *J. Mol. Biol.*, 183, pages 1-12 (1985); Ikuta et al., *Nucleic Acids Res.*, 15, pages 797-811 (1987); and Sambrook et al., Molecular Cloning, A Laboratory Manual, Second Edition, pages 11.7, 11.8 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989), incorporated herein by reference, have established helpful guidelines for the skilled practitioner to select the length of probes most sensitive to mismatches in standard hybridization protocols. For example, to detect a single mismatch in a specific DNA sequence of the mammalian genome by hybridization, a probe length of 14 to 20 nucleotides is recommended (see, for example, Sambrook et al., pages 11.7-11.8; Lathe, Table 6, page 10). Accordingly, DNA and RNA molecules including DNA sequences, or the corresponding RNA sequences, which include at least 14 consecutive nucleotides of SEQ ID NO. 5, or functionally equivalent molecules, for example, obtained by hybridization under stringent conditions or substitution of specific bases followed by screening for function, for use as probes in diagnostic hybridization methods to detect mutations in the 5' flanking region of the P-selectin gene of individuals with altered (for example, abnormally low or high) levels of expression of P-selectin. A whole series of nucleic acid probes including nucleotide sequences consisting essentially of 14 to 20 consecutive nucleotides of SEQ ID NO. 5 can be used to detect

mutations along the entire or a portion of the 5' flanking region of the P-selectin gene.

Standard methods to isolate DNA and RNA from mammalian cells and tissues are well known in the art and can be used to prepare DNA (or RNA) for routine diagnostic screening by hybridization using the probes described herein. See, for examples of methods known to those skilled in the art which can be adapted for use herein using routine variation, Sambrook et al., Molecular Cloning, A Laboratory Manual, Second Edition, pages 6.53-6.54 (DNA); pages 7.6-7.11 (RNA) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989); and Chomczynski and Sacchi, *Anal. Biochem.*, 162, pages 156-159 (1987) (RNA), the teachings of which are incorporated herein by reference. Furthermore, methods of carrying out hybridizations (for example, Southern and Northern blot methods) of nucleic acids immobilized on various supports, such as nylon membranes or nitrocellulose filters, using DNA probes described herein labelled with some standard detectable marker, for example, by using commercially available biotinylated, chemiluminescent, fluorescent, enzyme or radioactive labeling systems, are also routine and readily adapted to screening samples of DNA (or RNA) from individuals for alterations in the 5' flanking region of the P-selectin gene. See also, Leary et al., *Proc. Natl. Acad. Sci. USA*, 80, pages 4045-4049 (1983) (biotinylated probes); and Sambrook et al., Chapter 9 ("Analysis of Genomic DNA by Southern Hybridization"), Chapter 10 ("Preparation of Radiolabeled DNA and RNA Probes")). In addition to using membranes, the advantages of probing nucleic acid samples immobilized to the plastic wells of microtiter plates has recently been advocated, offering

another variation of the available methods of screening DNAs or RNAs by hybridization using nucleic acid probes (see Mitsuashi et al., *Nature*, 357, pages 519-520 (1992)). One of ordinary skill in the art is readily able to select from a variety of standard methods the particular conditions under which hybridizations are carried out in order to diagnostically screen DNA or RNA from individuals for alterations in the 5' flanking region of the P-selectin gene using the DNA molecules described herein as probes.

V. Therapeutic Methods and Compositions

As the above luciferase expression and the *lacZ* transgene expression studies indicate, nucleic acid molecules containing the 5' regulatory sequences of the P-selectin gene can be inserted into endothelial or megakaryocytic cells and used to regulate or inhibit heterologous gene expression *in vivo*. In the luciferase experiments, the plasmid pOLUC was used as the vector to carry and express the various recombinant 5' flanking region-luciferase gene constructs in endothelial cells. However, other vectors, including both plasmid and eukaryotic viral vectors, may be used to express a particular recombinant 5' flanking region-gene construct in endothelial or megakaryocytic cells depending on the preference and judgment of the skilled practitioner (see, for example, Sambrook et al., Chapter 16). Furthermore, a number of viral and nonviral vectors are being developed that enable the introduction of nucleic acid sequences *in vivo* (see, for example, Mulligan, *Science*, 260, pages 926-932 (1993); United States Patent No. 4,980,286; United States Patent No. 4,868,116; incorporated herein by reference). Recently, a delivery system was developed in which nucleic acid is encapsulated in cationic liposomes which can be

injected intravenously into a mammal. This system has been used to introduce DNA into the cells of multiple tissues of adult mice, including endothelium and bone marrow (see, for example, Zhu et al., *Science*, 261, pages 209-211 (1993); incorporated herein by reference).

The 5' flanking sequences of the P-selectin gene can also be used to inhibit the expression of the P-selectin gene in cells and thereby affect the inflammatory response. For example, an antisense RNA of all or a portion of the 5' flanking region of the P-selectin gene can be used to inhibit expression of P-selectin *in vivo*. Expression vectors (for example, retroviral expression vectors) are already available in the art which can be used to generate an antisense RNA of a selected DNA sequence which is expressed in a cell (see, for example, U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286). Accordingly, DNA containing all or a portion of the sequence of the 5' flanking region of P-selectin gene can be inserted into an appropriate expression vector so that upon passage into the cell, the transcription of the inserted DNA yields an antisense RNA that is complementary to the mRNA transcript of the P-selectin gene normally found in the cell. This antisense RNA transcript of the inserted DNA can then base-pair with the normal mRNA transcript found in the cell and thereby prevent the mRNA from being translated. It is of course necessary to select sequences of the 5' flanking region that are downstream from the transcriptional start sites for the P-selectin gene to ensure that the antisense RNA contains complementary sequences present on the mRNA. Based on the transcriptional start site analysis (see above and Figure 4) sequences between 4863 and 4842 of SEQ ID NO. 5 are most likely to be transcribed.

Accordingly, the DNA to be inserted into the expression vector for antisense therapy should at least contain these sequences.

Antisense RNA can be generated *in vitro* also,
5 and then inserted into cells. Oligonucleotides can be synthesized on an automated synthesizer (for example, Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). In addition, antisense
10 deoxyoligonucleotides have been shown to be effective in inhibiting gene transcription and viral replication (see, for example, Zamecnik et al., *Proc. Natl. Acad. Sci. USA*, 75, pages 280-284 (1978); Zamecnik et al., *PNAS*, 83, pages 4143-4146
15 (1986); Wickstrom et al., *Proc. Natl. Acad. Sci. USA*, 85, pages 1028-1032 (1988); Crooke, *FASEB J.*, 7, pages 533-539 (1993). Furthermore, recent work has shown that improved inhibition of expression of a gene by antisense oligonucleotides is possible if
20 the antisense oligonucleotides contain modified nucleotides (see, for example, Offensperger et al., *EMBO J.*, 12, pages 1257-1262 (1993) (*in vivo* inhibition of duck hepatitis B viral replication and gene expression by antisense phosphorothioate
25 oligodeoxynucleotides); Rosenberg et al., PCT WO 93/01286 (synthesis of sulfurthioate oligonucleotides); Agrawal et al., *Proc. Natl. Acad. Sci. USA*, 85, pages 7079-7083 (1988) (synthesis of antisense oligonucleoside
30 phosphoramidates and phosphorothioates to inhibit replication of human immunodeficiency virus-1); Sarin et al., *Proc. Natl. Acad. Sci. USA*, 85, pages 7448-7794 (1989) (synthesis of antisense methylphosphonate oligonucleotides); Shaw et al.,
35 *Nucleic Acids Res*, 19, pages 747-750 (1991) (synthesis of 3' exonuclease-resistant oligonucleotides containing 3' terminal

phosphoroamidate modifications); incorporated herein by reference).

The sequences of the 5' flanking region of P-selectin can also be used in triple helix (triplex) gene therapy. Oligonucleotides complementary to gene promoter sequences on one of the strands of the DNA have been shown to bind promoter and regulatory sequences to form local triple nucleic acid helices which block transcription of the gene (see, for example, Maher et al., *Science*, 245, pages 725-730 (1989); Orson et al., *Nucl. Acids Res.*, 19, pages 3435-3441 (1991); Postal et al., *Proc. Natl. Acad. Sci. USA*, 88, pages 8227-8231 (1991); Cooney et al., *Science*, 241, pages 456-459 (1988); Young et al., *Proc. Natl. Acad. Sci. USA*, 88, pages 10023-10026 (1991); Duval-Valentin et al., *Proc. Natl. Acad. Sci. USA*, 89, pages 504-508 (1992); Blume et al., *Nucl. Acids Res.*, 20, pages 1777-1784 (1992); Grigoriev et al., *J. Biol. Chem.*, 267, pages 3389-3395 (1992).

Recently, both theoretical calculations and empirical findings have been reported which provide guidance for the design of oligonucleotides for use in oligonucleotide-directed triple helix formation to inhibit gene expression. For example, oligonucleotides should generally be greater than 14 nucleotides in length to ensure target sequence specificity (see, for example, Maher et al., (1989); Grigoriev et al., (1992)). Also, many cells avidly take up oligonucleotides that are less than 50 nucleotides in length (see, for example, Orson et al., (1991); Holt et al., *Mol. Cell. Biol.*, 8, pages 963-973 (1988); Wickstrom et al., *Proc. Natl. Acad. Sci. USA*, 85, pages 1028-1032 (1988)). To reduce susceptibility to intracellular degradation, for example, by 3' exonucleases, a free amine can be introduced to a 3' terminal

hydroxyl group of oligonucleotides without loss of sequence binding specificity (Orson et al., 1991). Furthermore, more stable triplexes are formed if any cytosines that may be present in the
5 oligonucleotide are methylated, and also if an intercalating agent, such as an acridine derivative, is covalently attached to a 5' terminal phosphate (for example, via a pentamethylene bridge); again without loss of sequence specificity
10 (Maher et al., (1989); Grigoriev et al., (1992).

Methods to produce or synthesize oligonucleotides are well known in the art. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see, for
15 example, Sambrook et al., Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (see also, Ikuta et al., in *Ann. Rev. Biochem.*, 53, pages 323-356
20 (1984) (phosphotriester and phosphite-triester methods); Narang et al., in *Methods Enzymol.*, 65, pages 610-620 (1980) (phosphotriester method). Accordingly, DNA sequences of the 5' flanking region of the P-selectin gene described herein can
25 be used to design and construct oligonucleotides including a DNA sequence consisting essentially of at least 15 consecutive nucleotides of SEQ ID NO. 5, with or without base modifications or intercalating agent derivatives, for use in forming
30 triple helices specifically within the 5' flanking region of a P-selectin gene in order to inhibit expression of the gene in endothelial or megakaryocytic cells.

In addition, Rosenberg et al. (PCT WO
35 93/01286) teach the topical application of compositions including antisense oligonucleotides, generally 15-30 nucleotides in length, and

Pluronic™ (polypropylene oxide - polyethylene oxide block copolymer) gel, which is liquid at 4°C and solid at room temperature. Cells in direct contact with the gel compositions will take up the
5 antisense oligonucleotides which will then base-pair to the complementary mRNA and inhibit expression of the target gene. Other biodegradable polymers can be substituted for the pluronics™ such as the polylactic acid and polyglycolic acid
10 copolymers, polyethylene, and polyorthoesters which can be used to form implants for controlled release of the nucleic acid directly to a tissue where expression is desired.

Compositions including Pluronic™ gel and the
15 antisense oligonucleotides or oligonucleotides complementary to one of the strands of the 5' flanking region (for triplex formation) can be delivered locally to the endothelial cells in blood vessels by using a catheter which is advanced into
20 a vessel and applying the composition directly to the endothelial tissue. Other means of delivering such compositions locally to cells include using infusion pumps (for example, from Alza Corporation, Palo Alto, California) or incorporating the
25 compositions into polymeric implants (see, for example, P. Johnson and J.G. Lloyd-Jones, eds., Drug Delivery Systems (Chichester, England: Ellis Horwood Ltd., 1987), which can effect a sustained release of therapeutic compositions to the
30 immediate area of the implant.

Inhibition of Inflammation by inhibition of P-selectin expression.

The above methods and compositions may be used locally or systemically to inhibit the expression
35 of P-selectin in vivo and thereby inhibit inflammation. The ability to inhibit or otherwise regulate the inflammatory response at a site is desirable therapeutically because an inflammatory

response may cause damage to the host if unchecked, since leukocytes release many toxic molecules that can damage normal tissues. These molecules include proteolytic enzymes and free radicals. Examples of pathological situations in which leukocytes can cause tissue damage include injury from ischemia and reperfusion, bacterial sepsis and disseminated intravascular coagulation, adult respiratory distress syndrome, tumor metastasis, and atherosclerosis. Systemic administration of compounds to achieve chronic systemic down-regulation of P-selectin expression may also be useful, for example, in a chronic disorder such as rheumatoid arthritis.

There are a number of other common clinical disorders in which ischemia and reperfusion results in organ injury mediated by adherence of leukocytes to vascular surfaces, including strokes; mesenteric and peripheral vascular disease; organ transplantation; and circulatory shock (in this case many organs might be damaged following restoration of blood flow).

Bacterial sepsis and disseminated intravascular coagulation often exist concurrently in critically ill patients. They are associated with generation of thrombin, cytokines, and other inflammatory mediators, activation of platelets and endothelium, and adherence of leukocytes and aggregation of platelets throughout the vascular system. Leukocyte-dependent organ damage is an important feature of these conditions.

Adult respiratory distress syndrome is a devastating pulmonary disorder occurring in patients with sepsis or following trauma, which is associated with widespread adherence and aggregation of leukocytes in the pulmonary circulation. This leads to extravasation of large

amounts of plasma into the lungs and destruction of lung tissue, both mediated in large part by leukocyte products.

Two related pulmonary disorders that are often fatal are in immunosuppressed patients undergoing allogeneic bone marrow transplantation and in cancer patients suffering from complications that arise from generalized vascular leakage resulting from treatment with interleukin-2 treated LAK cells (lymphokine-activated lymphocytes). LAK cells are known to adhere to vascular walls and release products that are presumably toxic to endothelium. Although the mechanism by which LAK cells adhere to endothelium is not known, such cells could potentially release molecules that activate endothelium and then bind to endothelium by mechanisms similar to those operative in neutrophils.

Tumor cells from many malignancies (including carcinomas, lymphomas, and sarcomas) can metastasize to distant sites through the vasculature. The mechanisms for adhesion of tumor cells to endothelium and their subsequent migration are not well understood, but may be similar to those of leukocytes in at least some cases. The association of platelets with metastasizing tumor cells has been well described, indicating a role for platelets in the spread of some cancers.

Platelet-leukocyte interactions are believed to be important in atherosclerosis. Platelets might have a role in recruitment of monocytes into atherosclerotic plaques; the accumulation of monocytes is known to be one of the earliest detectable events during atherogenesis. Rupture of a fully developed plaque may not only lead to platelet deposition and activation and the

promotion of thrombus formation, but also the early recruitment of neutrophils to an area of ischemia.

Modifications and variations of the present invention, will be recognized by those skilled in the art from the foregoing detailed description.

5 It is understood that such modifications and variations are intended to come within the scope of this invention as defined in the specification, and that this invention is not limited by the specific

10 embodiments that have been presented by way of example.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Board of Regents of the University of Oklahoma
- (ii) TITLE OF INVENTION: Expression Control Sequences of the P-Selectin Gene
- (iii) NUMBER OF SEQUENCES: 17
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Patrea L. Pabst
 - (B) STREET: 1100 Peachtree Street, Suite 2800
 - (C) CITY: Atlanta
 - (D) STATE: GA
 - (E) COUNTRY: USA
 - (F) ZIP: 30309-4530
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Pabst, Patrea L.
 - (B) REGISTRATION NUMBER: 31,284
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (404)-815-6508
 - (B) TELEFAX: (404)-815-6555

(2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: synthetic DNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: yes
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 12
 - (D) OTHER INFORMATION: /function= "N is inosine."

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 15
 (D) OTHER INFORMATION: /function= "The nucleotide at position 15 can also be A or C."
 (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 28
 (D) OTHER INFORMATION: /function= "The nucleotide at position 28 can also be A, T, or C."
 (x) PUBLICATION INFORMATION:
 (A) AUTHORS: Johnston, G. I.
 Cook, R. G.
 McEver, Rodger P.
 (C) JOURNAL: Abstract 1238 Supplement II Circulation
 (D) VOLUME: 78
 (F) PAGE: II-310
 (G) DATE: October-1988
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCTGTCCACT GNCCGAGGTT GTCACAGCGC ACAAT

35

(2) INFORMATION FOR SEQ ID NO:2:
 (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: synthetic DNA
 (iv) ANTI-SENSE: yes

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(B) LOCATION: 12

(D) OTHER INFORMATION: /function= "N is inosine."

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(B) LOCATION: 15

(D) OTHER INFORMATION: /function= "The nucleotide at position 15 can also be A or C."

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(B) LOCATION: 28

(D) OTHER INFORMATION: /function= "The nucleotide at position 28 can also be C."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCTGTCCACT GNCCGAGGTT GTCACATCTC ACAAT

35

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3142 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGGGCAGAAG GCAGAAAACC AGCAGAGTCA CAGAGGAGAT GGCCAACTGC CAAATAGCCA	60
TCTTGTAACA GAGATTCCAG AGAGTGGTCT TTGGAATTTC CCAACTCCTT TGCTTCAGTG	120
CCCTGATCTC TGAACATAACA AACCAGAAAG AAGTGGCAGC ATGGACTTAT CATTACAGCA	180
CAAAGCATA CTCATGGAAT ATTTCGCGTA AATACTGCCA GAATCGGTAC ACAGACTTAG	240
TGGCCATCCA GAATAAAAAT GAAATTGATT ACCTCAATAA GGTCCTACCC TACTACAGCT	300

360 CCTACTACTG GATTGGGATC CGAAGAACA ATAAGACATG GACATGGGTG GGAACCAAAA
420 AGGCTCTCAC CAACGAGGCT GAGAACTGGG CTGATAATGA ACCTAACAAAC AAAAGGAACA
480 ACGAGGACTG CGTGGAGATA TACATCAAGA GTCCGTCAGC CCCTGGCAAG TGAATGATG
540 AGCACTGCTT GAAGAAAAAG CACGCATTGT GTTACACAGC CTCCTGCCAG GACATGTCCT
600 GCAGCAAAACA AGGAGAGTGC CTCGAGACCA TCGGGAAC TA CACCTGCTCC TGTACCCCTG
660 GATTCTATGG GCCAGAATGT GAATACGTGA GAGAGTGTGG AGAACTTGAG CTCCTCAAC
720 ACGTGTCTCAT GAACTGCAGC CACCCTCTGG GAACTTCTC TTTTAACTCG CAGTGCAGCT
780 TCCACTGCAC TGACGGGTAC CAAGTAAATG GGCCACAGCA GCTGGAATGC TTGGCTTCTG
840 GAATCTGGAC AAATAAGCCT CCACAGTGT TAGCTGCCCA GTGCCACCC CTGAAGATTC
900 CTGAACGAGG AAACATGATC TGCCTTCATT CTGCAAAAGC ATTCCAGCAT CAGTCTAGCT
960 GCAGCTTCAG TTGTGAAAGAG GGATTGTCAT TAGTTGGACC GGAAGTGGTG CAATGCACAG
1020 CCTCGGGGGT ATGGACAGCC CCAGCCCCAG TGTGTAAAGC TGTGCAGTGT CAGCACCTGG
1080 AAGCCCCCAG TGAAGGAACC ATGGACTGTG TTCATCCGCT CACTGCTTTT GCCTATGGCT
1140 CCAGCTGCAA ATTTGAGTGC CAGCCCCGGT ACAGAGTGAG GGGCTTGGAC ATGCTCCGCT
1200 GCATTGACTC TGGACACTGG TCTGCACCCCT TGCCAAACCTG TGAGGCTATT TCGTGTGAGC
1260 CGCTGGAGAG TCCTGTCCAC GGAAGCATGG ATTGCTCTCC ATCCTTGAGA GCGTTTCAGT
1320 ATGACACCAA CTGTAGCTTC CGCTGTGCTG AAGTTTTCAT GCTGAGAGGA GCCGATATAG
1380 TTCGGTGTGA TAACTTGGGA CAGTGGACAG CACCAGCCCC AGTCTGTCAA GCTTTGCAGT
1440 GCCAGGATCT CCCAGTTCCA AATGAGGCCC GGGTGAACTG CTCCCACCCC TTCGGTGCCT

TTAGGTACCA GTCAGTCTGC AGCTTCACCT GCAATGAAGG CTTGCTCCTG GTGGGAGCAA 1500
GTGTGCTACA GTGCTTGGCT ACTGGAAACT GGAATTCTGT TCCTCCAGAA TGCCAAGCCA 1560
TTCCCTGCAC ACCTTTGCTA AGCCCTCAGA ATGGAACAAT GACCTGTGTT CAACCTCTTG 1620
GAAGTTCCAG TTATAAATCC ACATGTCAAT TCATCTGTGA CGAGGGATAT TCTTTGTCTG 1680
GACCAGAAAG ATTGGATTGT ACTCGATCGG GACGCTGGAC AGACTCCCA CCAATGTGTG 1740
AAGCCATCAA GTGCCCAGAA CTCTTTGCCC CAGAGCAGGG CAGCCTGGAT TGTCTTGACA 1800
CTCGTGGAGA ATTCAATGTT GGCTCCACCT GTCATTTCTC TTGTAACAAT GGCTTTAAGC 1860
TGGAGGGGCC CAATAATGTG GAATGCCAAA CTTCTGGAAG ATGGTCAGCT ACTCCACCAA 1920
CCTGCAAAGG CATAGCATCA CTTCCCTACTC CAGGGTTGCA ATGTCCAGCC CTCACCACCTC 1980
CTGGGCAGGG AACCATGTAC TGTAGGCATC ATCCGGGAAC CTTTGGTTT AATACCACCTT 2040
GTTACTTTGG CTGCAACGCT GGATTACAC TCATAGGAGA CAGCACTCTC AGCTGCAGAC 2100
CTTCAGGACA ATGGACAGCA GTAACTCCAG CATGCAGAGC TGTGAAATGC TCAGAACTAC 2160
ATGTTAATAA GCCAATAGCG ATGAACTGCT CCAACCTCTG GGGAAACTTC AGTTATGGAT 2220
CAATCTGCTC TTTCCATTGT CTAGAGGGCC AGTTACTTAA TGGCTCTGCA CAAACAGCAT 2280
GCCAAGAGAA TGGCCACTGG TCAACTACCG TGCCAACCTG CCAAGCAGGA CCATTGACTA 2340
TCCAGGAAGC CCTGACTTAC TTTGGTGGAG CGGTGGCTTC TACAATAGGT CTGATAATGG 2400
GTGGGACGCT CCTGGCTTTG CTAAGAAAGC GTTTCAGACA AAAAGATGAT GGGAAATGCC 2460
CCTTGAATCC TCACAGCCAC CTAGGAACAT ATGGAGTTT TACAAACGCT GCATTTGACC 2520
CGAGTCCTTA AGGTTTCCAT AAACACCCAT GAATCAAAGA CATGGAATTA CCTAGATTA 2580

GCTCTGGACC AGCCTGTTGG ACCCGCTCTG GACCAACCCT GTTTCCTGAG TTGCGGATTG 2640
 TGGTACAATC TCAAATTCTC AACCTACCAC CCCTTCCTGT CCCACCTCTT CTCTTCCCTGT 2700
 AACACAAAGC ACAGAAGCCA GGAGCAAATG TTCTGCGAGT AGTCTCTGTG CTTTGACTCA 2760
 CCTGTTACTT GAAATACCAG TGAACCAAAG AGACTGGAGC ATCTGACTCA CAAAGAAGACC 2820
 AGACTGTGGA GAAATAAAAA TACCTCTTTA TTTTGTGATT GAAGGAAGGT TTCTCTCCACT 2880
 TTGTTGGAAA GCAGGTGGCA TCTCTAATTG GAAGAAATTC CTGTAGCATC TTCTGGAGTC 2940
 TCCAGTGGTT GCTGTTGATG AGGCCTCTTG GACCTCTGCT CTGAGGCTTC CAGAGAGTCC 3000
 TCTGGATGGC ACCAGAGGCT GCAGAAGGCC AAGAATCAAG CTAGAAGGCC ACATGTCACC 3060
 GTGGACCTTC CTGCCACCAG TCACTGTCCC TCAATGACC CAAAGACCAC TATTCAAATG 3120
 CGTAATAAAA AGAATTTTCC CC 3142

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 830 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ala Asn Cys Gln Ile Ala Ile Leu Tyr Gln Arg Phe Gln Arg Val
 1 5 10 15
 Val Phe Gly Ile Ser Gln Leu Leu Cys Phe Ser Ala Leu Ile Ser Glu
 20 25 30
 Leu Thr Asn Gln Lys Glu Val Ala Ala Trp Thr Tyr His Tyr Ser Thr
 35 40 45

Lys Ala Tyr Ser Trp Asn Ile Ser Arg Lys Tyr Cys Gln Asn Arg Tyr
 50 55 60
 Thr Asp Leu Val Ala Ile Gln Asn Lys Asn Glu Ile Asp Tyr Leu Asn
 65 70 75 80
 Lys Val Leu Pro Tyr Tyr Ser Ser Tyr Tyr Trp Ile Gly Ile Arg Lys
 85 90 95
 Asn Asn Lys Thr Trp Thr Trp Val Gly Thr Lys Lys Ala Leu Thr Asn
 100 105 110
 Glu Ala Glu Asn Trp Ala Asp Asn Glu Pro Asn Asn Lys Arg Asn Asn
 115 120 125
 Glu Asp Cys Val Glu Ile Tyr Ile Lys Ser Pro Ser Ala Pro Gly Lys
 130 135 140
 Trp Asn Asp Glu His Cys Leu Lys Lys Lys His Ala Leu Cys Tyr Thr
 145 150 155 160
 Ala Ser Cys Gln Asp Met Ser Cys Ser Lys Gln Gly Glu Cys Leu Glu
 165 170 175
 Thr Ile Gly Asn Tyr Thr Cys Ser Cys Tyr Pro Gly Phe Tyr Gly Pro
 180 185 190
 Glu Cys Glu Tyr Val Arg Glu Cys Gly Glu Leu Glu Pro Gln His
 195 200 205
 Val Leu Met Asn Cys Ser His Pro Leu Gly Asn Phe Ser Phe Asn Ser
 210 215 220
 Gln Cys Ser Phe His Cys Thr Asp Gly Tyr Gln Val Asn Gly Pro Ser
 225 230 235 240

Lys Leu Glu Cys Leu Ala Ser Gly Ile Trp Thr Asn Lys Pro Pro Gln
 245 250 255
 Cys Leu Ala Ala Gln Cys Pro Pro Leu Lys Ile Pro Glu Arg Gly Asn
 260 265 270
 Met Ile Cys Leu His Ser Ala Lys Ala Phe Gln His Gln Ser Ser Cys
 275 280 285
 Ser Phe Ser Cys Glu Glu Gly Phe Ala Leu Val Gly Pro Glu Val Val
 290 295 300
 Gln Cys Thr Ala Ser Gly Val Trp Thr Ala Pro Ala Pro Val Cys Lys
 305 310 315 320
 Ala Val Gln Cys Gln His Leu Glu Ala Pro Ser Glu Gly Thr Met Asp
 325 330 335
 Cys Val His Pro Leu Thr Ala Phe Ala Tyr Gly Ser Ser Cys Lys Phe
 340 345 350
 Glu Cys Gln Pro Gly Tyr Arg Val Arg Gly Leu Asp Met Leu Arg Cys
 355 360 365
 Ile Asp Ser Gly His Trp Ser Ala Pro Leu Pro Thr Cys Glu Ala Ile
 370 375 380
 Ser Cys Glu Pro Leu Glu Ser Pro Val His Gly Ser Met Asp Cys Ser
 385 390 395 400
 Pro Ser Leu Arg Ala Phe Gln Tyr Asp Thr Asn Cys Ser Phe Arg Cys
 405 410 415
 Ala Glu Gly Phe Met Leu Arg Gly Ala Asp Ile Val Arg Cys Asp Asn
 420 425 430

Leu Gly Gln Trp Thr Ala Pro Ala Pro Val Cys Gln Ala Leu Gln Cys
 435 440 445
 Gln Asp Leu Pro Val Pro Asn Glu Ala Arg Val Asn Cys Ser His Pro
 450 455 460
 Phe Gly Ala Phe Arg Tyr Gln Ser Val Cys Ser Phe Thr Cys Asn Glu
 465 470 475 480
 Gly Leu Leu Val Gly Ala Ser Val Leu Gln Cys Leu Ala Thr Gly
 485 490 495
 Asn Trp Asn Ser Val Pro Pro Glu Cys Gln Ala Ile Pro Cys Thr Pro
 500 505 510
 Leu Leu Ser Pro Gln Asn Gly Thr Met Thr Cys Val Gln Pro Leu Gly
 515 520 525
 Ser Ser Ser Tyr Lys Ser Thr Cys Gln Phe Ile Cys Asp Glu Gly Tyr
 530 535 540
 Ser Leu Ser Gly Pro Glu Arg Leu Asp Cys Thr Arg Ser Gly Arg Trp
 545 550 555 560
 Thr Asp Ser Pro Pro Met Cys Glu Ala Ile Lys Cys Pro Glu Leu Phe
 565 570 575
 Ala Pro Glu Gln Gly Ser Leu Asp Cys Ser Asp Thr Arg Gly Glu Phe
 580 585 590
 Asn Val Gly Ser Thr Cys His Phe Ser Cys Asn Asn Gly Phe Lys Leu
 595 600 605
 Glu Gly Pro Asn Asn Val Glu Cys Thr Thr Ser Gly Arg Trp Ser Ala
 610 615 620

Thr Pro Pro Thr Cys Lys Gly Ile Ala Ser Leu Pro Thr Pro Gly Leu
 625 630 640
 Gln Cys Pro Ala Leu Thr Thr Pro Gly Gln Gly Thr Met Tyr Cys Arg
 645 650 655
 His His Pro Gly Thr Phe Gly Phe Asn Thr Thr Cys Tyr Phe Gly Cys
 660 665 670
 Asn Ala Gly Phe Thr Leu Ile Gly Asp Ser Thr Leu Ser Cys Arg Pro
 675 680 685
 Ser Gly Gln Trp Thr Ala Val Thr Pro Ala Cys Arg Ala Val Lys Cys
 690 695 700
 Ser Glu Leu His Val Asn Lys Pro Ile Ala Met Asn Cys Ser Asn Leu
 705 710 715 720
 Trp Gly Asn Phe Ser Tyr Gly Ser Ile Cys Ser Phe His Cys Leu Glu
 725 730 735
 Gly Gln Leu Leu Asn Gly Ser Ala Gln Thr Ala Cys Gln Glu Asn Gly
 740 745 750
 His Trp Ser Thr Thr Val Pro Thr Cys Gln Ala Gly Pro Leu Thr Ile
 755 760 765
 Gln Glu Ala Leu Thr Tyr Phe Gly Gly Ala Val Ala Ser Thr Ile Gly
 770 775 780
 Leu Ile Met Gly Gly Thr Leu Leu Ala Leu Leu Arg Lys Arg Phe Arg
 785 790 795 800
 Gln Lys Asp Asp Gly Lys Cys Pro Leu Asn Pro His Ser His Leu Gly
 805 810 815

Thr Tyr Gly Val Phe Thr Asn Ala Ala Phe Asp Pro Ser Pro
820 825 830

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4866 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

AAGCTTCCTG TACCTGGAAT ATTAATATTT TATTTCAGAT TTGGGAAATT TTCAGCTAGC    60
AATCTTTAAA TATGCTTTCT GACCCCTTTT TCCTCTATTTT TCTCCTTCTT AAACACTACTGT    120
AATGTGAACA TTAGCTCTCT TTTTAAATTT TTAATTTAAT TTTTGTTTT ATTTTGTGAG    180
ATGCAGTCTC ACTCTGTCAC CCAGGCTGGA GTGCAGTGGC ATGATCTCAG CTCACCTGCAA    240
CCTTTGCCCT CTAGGTTGAA GAGATTCTGC TGCCTCAGTC TCCCCATGAG CTGGGATTAC    300
AGCATGTGCC ACAATCCCCTG GCTAATTTTT TTGTATTTTT AGTAGAGACT GGGTTTCACC    360
ATGTTGGTCA GGCTGGTCTT GACTCCTGAC CTCAGGTGAT CCACTCACCT TGGCCTCCCA    420
AAGCGCTGGG ATTATGGCAT GAGCCACTGA GTCTGGCTGA ATGTTAGCTC TCTTGATGCT    480
GTCCCATAAA TCTTGTAGGC TTTCATCATTT TCTTTTCATT CTTTTTCTC CTCTCACTGT    540
ATATTTTCAA AAACCTGTCT TCAGTTCACA GATTCTTTCT TCTGCTTGAT CAAGTCTGCT    600
ACTGGTGATT TCTACTGCAT TTCTCACTTC ATTCAATTATA TTTTTCAGCT CCAATTTCTT    660
TTATGATTTT AATCTTTCTG TTACATTTCT TATGTTGTGC ATTTATTGTT TCTCTGATTT    720
CACCAAATTG TTTCTCTGTG TTTGCTTCAA AGTAACTGAG CTTCTTTAAA AACAAATTATC    780

```

TTGAATCCAT TGT CAGGCCA TTTGTAGTAC TCCATTTCTT TTGGGTCAGC TACTGGAAA 840
TTATTGTGTT TCTTAGGTGG TGATATTTTA ATTTGGGTTT TCAATGTTTCT TGCTGCCCTTA 900
CACTGCTGTC TGAGCATCTG GTGGATCTGC CCCAATTCA GGTGTATGG GCTGACTTTG 960
GTGGAGAAAT ACCTTCTTAT GTGGAATAAT GCGAGGATGC TGGCTGGGTG GGATGCAAAA 1020
GTTCTGACTT CAGTAGGGGC AAAGCTGTGT GGTCTCCAAG CAGATCTGTC AGCTGAGGTT 1080
GGTGTAGTG AATACTACAG GGATCCTTAG AGGCCAACAC TGTGGGTATC TACAGTGGCA 1140
ATGAGGCTGT TGAGGTTTTC AATTGTGACA AGTCTCCAT ATCTCTTTT TTCCCCACCT 1200
GGGAAGTCAT GACTGAGGAC ATCCCTCTTG GAATTAGGTC TAACTTGTCAG GCCTGCTCCT 1260
GGTGGTGGTG ACACTGGTGT CTGATGAACA GTGCCCATGG AGTGGCCAAG AGCCAAGGCC 1320
TGAAGCATGG GCATGCATGG AGGACCACA GCACCAGATT CAATTGTAGC AATGGTACCA 1380
GTGCCCCAAG CACAGGCATA CTTACTATCA CATTGATAAT GGTGTGTAAA ATGCAGGTAC 1440
TTATAAAGCA GCTAAGGAGC CAGGGACTTT ACTGCATGCA TACGCAGAGC TACAGTGGCT 1500
CCAGGATCCA GGGTGTGGGC TAGCTCTCCT TGGTGGCTGA GCTGGTGAAT AGAGCATGGA 1560
CAGGCACAGA GAAACCTTGA CTCTAGGACC CAGGGTGTTT ACTAGCTCAC TATAGTGGTG 1620
GCTCTGGTGT TGGAGGTGTG GGTGTGTGTA GTACAGCCTC AGAGACAGGG TCTGGAGCGC 1680
AGGTGTGCAC ATTACTACAG CAGCTCTGGA GTTGAGAATA TGGGTTACCT TTCTACAGTG 1740
GCTGAAGTAG TGTCTGGAGC AAAGACTTTC ACAGAGAGAA CTTGGCTTGG GGTCCCAGGG 1800
TGAGATCTAG TTCACAACAG CAGTGACTCC AGTGTCTGAG ACATGAGGAG GTGCACTGCA 1860
GCCACAGAGC CACAGTCCAG AGTGTGAATA TCTGTAGAGC AGCCACAACCT TTTGGGGATC 1920

AGGAACACAC ATAGAATTGT GAGAGGTGGT AACCCCTGGCC CCAGTCCTGG CGAGTGCAAC 1980
AATAGCTGCT TCTTGGTGAG GGGGTGTGAG GGGTAGTGCA ACTGTGTTTC CCTTTTTAGC 2040
ATCCTGCTAT GGGAAATGGCT GTTGGACAAA AGATGCCAGT GTCCTCTGTG GAGCAGGACA 2100
CTGGGGCCCT CAGTGGCTCT GTGTCACATG ACTGACACAG ATAGCCTACA AATTTCCTTA 2160
TTCTGTAGCTA TCTCCTGGTG TCTCATATAT GCCAGTCTCA CCGGTGATTC TTCTACATGA 2220
ATATTCTTTC TTTTCTCCAT TGTGTGTGTC CAAATTCTTT AACAGGCTCT TGAGCCCCCAT 2280
CCCCCAACTC CCCACCCCTG TGAGGGCTAT TTTGGTTTGT GTATAACTGT CTATGTTTGT 2340
TTTTTTTGTG GGGCATAAGG CTGACATCTC CTACTCCACC ATCTTGCTAA TGTCACTGTC 2400
ATAGGAATCT TTTTATGCTT TCCTTATATT CACTAAAATT TAACAATATC AAACCTTAAAA 2460
ACATATGATC AATTGAACCT ATTAATATCA AACTTATTAT AAATAAGAAA CTACCAGGCT 2520
GGGCATGGTG GCTCATGCCT GTAATCCCAA CATTTTGGGA GGCTGAGGTG AAAGGATCAC 2580
TTGAGCCCAG GAATTCAAGA CCAGCCCTGGG AAATATAGAG AGACCCPATC TCTAGAGATT 2640
TTTTTTTTTA ATTAGCCAGT AGTGATGGCA CACATCTATA GTCCCAGCTA CTCAGGAGGC 2700
TGAGGTGGGA GAATTGCTTG AGCCCAGGAG GTCAAGGCTG CAGCAAGCAG TAATCATGCC 2760
ACTGCACTCC AGCCTGGGCC GCAGAGTGAG ACCCTGTCTC AAAAAAAGAA CCTACTAGTC 2820
TACATACCAC ACTTCTTCAT CCCCATCTGA GACTATATAT ATTTTCTTA ACATGAGGCA 2880
ATGCCAAAAA GAGGAGCTGG TGAGTGAAAG TAAGAACAGA AAGACATGGA GGCAAGTCTT 2940
ATAGAATAAT AGCCAACACT TAAACTTACA CTTAACAGCG TGATAGGTAT TGTTCCAAAC 3000
ACATTAAATT CATTTAATGG TCCTTACATG TCTATGTATT TGGTGATTAT TATCCTTATT 3060

ATTACATTG CTGAGTGTAT TATTCTGTTC TCATGATGCT GATAGAGACA TACCCGAGAC 3120
TGGATAACTT ATTAATAAAA AAAAGGTTTA ATGGACTCAC AGTTCCACGT GGATGGGGAG 3180
TCCTCACAAAT CATGGTAGAA AGCAAAAGAC ACGTCTTACA TGGCAGCAGG GAAGAGAGAG 3240
AAATGAGAAC CAAACAAAAG GGGTTTCCCC TTATAAAACC ATCAGCTCTC ATGCCACTTA 3300
TTCACCTACCA TGAGAACACAGT ATGGGGGAAA CCACCCCCAT GATTCAATGA TCTACCAGGT 3360
GCCTCCACCA ACCTGTGGGA ATTATGGGAG CTACAATTCC AGATGAGATT TGGGTGGGGA 3420
CACAGCCAAA CCACATCACT GAGGAAACTG AGTTATAGGG AGATTAGTAA CGCCCAACAC 3480
AGCTGGTAGG TGGTGGAGCC AGGCAGTCTG ACTCTAGGGT CTGGACTCTG AACTGCATCA 3540
TGCTGCCAAG AAGTTCCTCA TTTTTCCTC TCTCTAAGTT TCCCTTATTC CCCTACAGTC 3600
ATTCCCTCAA CAGCATTTC TACCATCTT TTTCTACTTC TACTATATAA TTAATTTTTT 3660
CTTCTTGGTC CCAAATTCCA ACGTGCAAAT GCAGCCTTAT ATACCCTAAT TCATCTTTAC 3720
CTTTAGACTT TCTTCCAATG TTTCTACTTC ATTCCATTTT AAATTTATCC ATGAGATGCC 3780
TATTTACAAG CTGTAACCAT CATGAAGTGA ATGAAGAATA ATACCTACTA CTGTACAATA 3840
GAATTCCAAG AGTATAAATA GGAGTTATGG CTTTCTGACT TGAAACTAAA TACTTGATAC 3900
TTGATTTTGC TGTCTGAGAT CAATCTGAAA AGTAATAATA ATCACTAACA TTTGTTGAGC 3960
ATCAATTGTG GGCCAAGTGT CATTTCATC ACTCTGTACA TATTAACTCA TTTTCATCCTA 4020
CAACAACCCG GTGAGGCAAG TTCTGTATT TTCTTTTACA GTTGAGGAAA CAGAGGCATA 4080
GAGAGCTTAA GTAGTTTGCC CAGTAGATAG CCAGAAGAGG AGCCAGGATG GGTCTCGGGC 4140
AGTTTAAACAG CACAGCTGAA GTCTTAACCA CTATGCCAAC AGCTTTTGG TCCTACACAT 4200

67

CCCATGGGAA GAGGAAAATA AAAAGGTATC TATTGTATA CCTTTTATT TCTGATATAA 4260
 GAAGCAGAAT TCCTTTCACA TGACCTATGT CTATTFAATA CGTCATTTTG AAACCTIACCA 4320
 ATAAAATTTC CCAAGCGCCA GAAAACTGTT AGTGGCTTTT TCCATTCTTC TCTATTTTTT 4380
 TTTGTGCTAC TAAATTTGCT TCTTTCCCTC AGAAGGCTGC CGGAATAGTA AACATTCACT 4440
 GACATGTCAT AATTACTGGA AAATGGGCAC TGGAAAAATCA CATTGTAATT AATTCAAAGC 4500
 ATGTTTCCCA AATGTACTAC TTFAAATTGG AGCTTATATC ATAATCCAAG GAAACCTTTG 4560
 TGTGTGTACT GTTCCACACAT TGCTCAGCCT GGGATATCCA GGAGTAATC ACCTTGCGCC 4620
 TGCCTCCAGA CCATCTTCCA TGAAGGGGG TGACCCCTTG CCTCTGGCA ACCACTATTT 4680
 CTAAGCTGCC AACATTACTC TTGCATTATC AACATTCTAA CTTCATGGGA AGGGCTGTGG 4740
 TGAGTTTCTG GAATGTGAAT AGGAAGTTGT TTTTCTAAAC AGCCTGACAC TGAGGGGAGG 4800
 CAGTGAGACT GTAAGCAGTC TGGTTGGGC AGAAGGCAGA AAACCAGCAG AGTCACAGAG 4860
 GAGATG 4866

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTCTGGTTTG TTAGTTCAGA GATCAGG

27

68

25

- (2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GATGTATATC TCCACGCAGT CCTCG

35

- (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GAATTCGAGC TCGGTACCTT TTTTTTTTTT TTTT

18

- (2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAATTCGAGC TCGGTACC

- (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid

30

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: synthetic DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GTCGACTCTA GAATCAGCCC AGTTCTCAGC

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CGGCTGGGA TTCCCCATCT

20

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: synthetic DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTTGGTTCCA AG

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTTGGTTTAA AG

12

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CTTCCATCCA AG

12

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TCGAGCAGGA AGTGACGTCG A

21

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGCCAAACCG GAAGCATGTG

20

- (2) INFORMATION FOR SEQ ID NO:17:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 34 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AGCTTGCGGA ACGGAAGCGG AAACCGCCGG ATCG

We claim:

1. A method for the regulated expression of a gene in endothelial cells or megakaryocytes comprising fusing the 5' end of the coding sequence of the gene to the 3' end of a DNA molecule comprising a nucleotide sequence consisting essentially of nucleotides 1 to 4863 of SEQ ID NO. 5, or portions thereof effective to control expression of a gene, to yield a recombinant gene construct; inserting the recombinant gene construct into endothelial cells or megakaryocytes; and assaying for expression of the recombinant gene inserted into the endothelial cells or megakaryocytes.

2. The method of claim 1 for the regulated expression of a gene encoding a protein wherein the 5' end of the coding sequence of the gene is fused to the 3' end of a DNA molecule comprising a nucleotide sequence of at least eight contiguous nucleotides of a sequence selected from the group consisting of nucleotides 1 to 4863, 1 to 4851, 3525 to 4851, 3525 to 4863, 3732 to 4866, 4163 to 4851, 4163 to 4863, 4206 to 4866, 4212 to 4866, 4405 to 4851, 4405 to 4863, 4446 to 4469, 4453 to 4461, 4457 to 4866, 4471 to 4866, 4505 to 4866, 4555 to 4666, 4555 to 4851, 4555 to 4863, 4615 to 4666, 4615 to 4764, 4615 to 4851, 4615 to 4861, 4615 to 4863, 4626 to 4650, 4632 to 4672, 4635 to 4646, 4636 to 4645, 4641 to 4866, 4642 to 4664, 4645 to 4866, 4646 to 4650, 4646 to 4657, 4650 to 4669, 4667 to 4863, 4667 to 4717, 4717 to 4863, 4722 to 4731, 4727 to 4866, 4747 to 4757, 4734 to 4758, 4736 to 4764, 4736 to 4863, 4745 to 4753, 4761 to 4866 of SEQ ID NO. 5, and combinations thereof.

3. The method of claim 1 wherein the gene encodes P-selectin.

4. A method for screening for defects in the 5' flanking region of the P-selectin gene of individuals comprising hybridizing nucleic acid from cells of the individuals to a nucleic acid probe molecule comprising a nucleotide sequence consisting essentially of nucleotides 1 to 4863 of SEQ ID NO. 5, or portions thereof consisting essentially of at least fourteen consecutive nucleotide bases.

5. The method of claim 4 wherein the cells are selected from the group consisting of megakaryocytes and endothelial cells.

6. The method of claim 4 wherein the probe molecule comprises a nucleotide sequence consisting essentially of sequences selected from the group consisting of any one of the sequences defined by nucleotides 1 to 4851, 3525 to 4851, 3525 to 4863, 3732 to 4866, 4163 to 4851, 4163 to 4863, 4206 to 4866, 4212 to 4866, 4405 to 4851, 4405 to 4863, 4446 to 4469, 4453 to 4461, 4457 to 4866, 4471 to 4866, 4505 to 4866, 4555 to 4666, 4555 to 4851, 4555 to 4863, 4615 to 4666, 4615 to 4764, 4615 to 4851, 4615 to 4861, 4615 to 4863, 4626 to 4650, 4632 to 4672, 4635 to 4646, 4636 to 4645, 4641 to 4866, 4642 to 4664, 4645 to 4866, 4646 to 4650, 4646 to 4657, 4650 to 4669, 4667 to 4863, 4667 to 4717, 4717 to 4863, 4722 to 4731, 4727 to 4866, 4747 to 4757, 4734 to 4758, 4736 to 4764, 4736 to 4863, 4745 to 4753, 4761 to 4866 of SEQ ID NO. 5, and combinations thereof.

7. An isolated nucleic acid molecule comprising a nucleotide sequence consisting essentially of nucleotides 1 to 4863 of SEQ ID NO. 5, or portions thereof consisting essentially of at least fourteen consecutive nucleotides of SEQ ID NO. 5.

8. The isolated nucleic acid molecule of claim 7 comprising a nucleotide sequence consisting essentially of the consecutive nucleotides of SEQ ID NO. 5 selected from the group consisting of nucleotides 1 to 4851, 3525 to 4851, 3525 to 4863, 3732 to 4866, 4163 to 4851, 4163 to 4863, 4206 to 4866, 4212 to 4866, 4405 to 4851, 4405 to 4863, 4446 to 4469, 4453 to 4461, 4457 to 4866, 4471 to 4866, 4505 to 4866, 4555 to 4666, 4555 to 4851, 4555 to 4863, 4615 to 4666, 4615 to 4764, 4615 to 4851, 4615 to 4861, 4615 to 4863, 4626 to 4650, 4632 to 4672, 4635 to 4646, 4636 to 4645, 4641 to 4866, 4642 to 4664, 4645 to 4866, 4646 to 4650, 4646 to 4657, 4650 to 4669, 4667 to 4863, 4667 to 4717, 4717 to 4863, 4722 to 4731, 4727 to 4866, 4747 to 4757, 4734 to 4758, 4736 to 4764, 4736 to 4863, 4745 to 4753, 4761 to 4866 of SEQ ID NO. 5, and combinations thereof.

9. The isolated nucleic acid molecule of claim 7 further comprising a gene, wherein the 5' end of the gene is ligated to the 3' end of the nucleic acid molecule.

10. The isolated nucleic acid molecule of claim 9 inserted into cells capable of expressing the ligated gene.

11. The isolated nucleic acid molecule of claim 10 wherein the ligated gene is inserted into the cells in an expression vehicle capable of replicating in the cells.

12. The isolated nucleic acid molecule of claim 10 wherein the ligated gene is stably incorporated into the genome of the cells.

13. The isolated nucleic acid molecule of claim 12 wherein the cells are transgenic animals.

14. The isolated nucleic acid molecule of claim 7 inserted into an expression vector.

15. The isolated nucleic acid molecule of claim 14 wherein the vector is a retroviral vector.

16. The isolated nucleic acid molecule of claim 7 further comprising a pharmaceutically acceptable carrier for administration to a person in need of treatment thereof.

17. The isolated nucleic acid molecule of claim 16 wherein the carrier is a polymeric material providing controlled release of the nucleic acid molecule.

18. The isolated nucleic acid molecule of claim 7 wherein an intercalating agent is covalently linked to a 5' terminal phosphate.

19. The isolated nucleic acid molecule of claim 18 wherein the intercalating agent is an acridine.

20. The isolated nucleic acid molecule of claim 7 wherein an amine is covalently linked to a 3' terminal hydroxyl group.

21. The isolated nucleic acid molecule of claim 7 wherein cytosine residues are methylated.

22. A method of inhibiting P-selectin expression in cells expressing P-selectin comprising inserting into the cells a nucleic acid molecule comprising a nucleotide sequence consisting essentially of at least fifteen consecutive nucleotides of SEQ ID NO. 5.

23. The method of claim 22 for the regulated expression of a gene encoding a protein wherein the 5' end of the coding sequence of the gene is fused to the 3' end of a DNA molecule comprising a nucleotide sequence consisting essentially of sequences selected from the group consisting of sequences between nucleotide 4769 and nucleotide 1 of SEQ ID No. 5.

24. The method of claim 22 comprising inserting into the cells a nucleotide sequence forming a triplex structure with any of the sequence between nucleotides 4864 and 1 of SEQ ID No. 5.

25. A method for isolating a gene transcriptional regulatory protein, or functional DNA-binding peptide portion thereof, comprising binding to the regulatory protein or peptide portion, an isolated DNA molecule comprising a nucleotide sequence of at least eight contiguous nucleotides of SEQ ID NO. 5.

26. The method of claim 25 for isolating a gene transcriptional regulatory protein, or functional DNA-binding peptide portion thereof, comprising binding to the regulatory protein or peptide portion, an isolated DNA molecule comprising a nucleotide sequence consisting essentially of sequences selected from the group consisting of nucleotides 1 to 4863, 1 to 4851, 3525 to 4851, 3525 to 4863, 3732 to 4866, 4163 to 4851, 4163 to 4863, 4206 to 4866, 4212 to 4866, 4405 to 4851, 4405 to 4863, 4446 to 4469, 4453 to 4461, 4457 to 4866, 4471 to 4866, 4505 to 4866, 4555 to 4666, 4555 to 4851, 4555 to 4863, 4615 to 4666, 4615 to 4764, 4615 to 4851, 4615 to 4861, 4615 to 4863, 4626 to 4650, 4632 to 4672, 4635 to 4646, 4636 to 4645, 4641 to 4866, 4642 to 4664, 4645 to 4866, 4646 to 4650, 4646 to 4657, 4650 to 4669, 4667 to 4863, 4667 to 4717, 4717 to 4863, 4722 to 4731, 4727 to 4866, 4747 to 4757, 4734 to 4758, 4736 to 4764, 4736 to 4863, 4745 to 4753, 4761 to 4866 of SEQ ID NO. 5, and combinations thereof.

27. A transcription regulatory protein or functional DNA-binding peptide portion thereof, isolated by a method comprising binding the protein or peptide thereof, to an isolated DNA molecule comprising a nucleotide sequence consisting essentially of at least eight contiguous nucleotides of SEQ ID NO. 5.

28. The transcription regulatory protein or functional DNA-binding peptide portion thereof, of claim 27, isolated by a method comprising binding the protein or peptide thereof, to an isolated DNA molecule comprising a nucleotide sequence consisting essentially of sequences selected from the group consisting of nucleotides 1 to 4863, 1 to 4851, 3525 to 4851, 3525 to 4863, 3732 to 4866, 4163 to 4851, 4163 to 4863, 4206 to 4866, 4212 to 4866, 4405 to 4851, 4405 to 4863, 4446 to 4469, 4453 to 4461, 4457 to 4866, 4471 to 4866, 4505 to 4866, 4555 to 4666, 4555 to 4851, 4555 to 4863, 4615 to 4666, 4615 to 4764, 4615 to 4851, 4615 to 4861, 4615 to 4863, 4626 to 4650, 4632 to 4672, 4635 to 4646, 4636 to 4645, 4641 to 4866, 4642 to 4664, 4645 to 4866, 4646 to 4650, 4646 to 4657, 4650 to 4669, 4667 to 4863, 4667 to 4717, 4717 to 4863, 4722 to 4731, 4727 to 4866, 4747 to 4757, 4734 to 4758, 4736 to 4764, 4736 to 4863, 4745 to 4753, 4761 to 4866 of SEQ ID NO. 5, and combinations thereof.

-41-

AGHPE4

I TCGCCAGCAAGCCGCAAAACCACGACAGTCTCACAGCAGATC H

→ AGHPE1

42 GCGAAGTCGCAATAGCATCTGTACAGAGATTCGAGAGAGTGCTTTGGGAATTTCCCAACTCTTTGCTTCTAGTGCCTGTATCTCTGAAGTAACAACCAAGCAAGAAGTGGCAGCA
AN Q I A I L Y Q R P Q R V V F G I S Q L L C F S A L I S E L T N Q K E V A A

162 TGCACTTATCATACAGCACAAGCATACTCATGGAATTTCCGTAATACTGCCAGAAATCGCTACACAGACTTAGTGCCATCCAGAAATAAAAATGAAATTGATTACTCTCAATAAG
W T Y H Y S T K A Y S W N I S R K Y Q N R Y T D L V A I Q N K N E I D Y L N K

282 GTCTACCTACTACAGCTCTACTACTGGAATTCGATCCGAAGACAATAAGACATGCACATCGGTGGCAACCAAAAGCTCTCACCAAGCAGCTCGAACCTGGCGCTGATATGAA
V L P Y Y S S Y Y W I G I R K N N K T W T W V G T K K A L T N E A E N W A D N E

402 CCTACCAAGGAACAACGAGCCTCGCTCGAGATATACATCAAGACTCCGTGAGCGCTGCAACTGGAATGATGAGCACTGCTTGAAGAAAAAGCAGCATTTGTGTTACAGGCC
P N N K R N N E D V E I Y I K S P S A P G K W N D E M L K K K H A L C Y T A

522 TCCTGCCAGGAGATGCTGTCAGCAAAAGCAGAGTGCCTCGAGACCATCGGAATACACCTGCTCTGTTACCTGGATTCTATGGCCAGAAATGTGAATACGTGAGAGAGTGTGGA
S Q D H S S K Q G E L E T I G N Y T S Y P G P Y G P E E Y V R E C G

→ AGHPE2

642 GAAGTTGAGCTCCCTCAACAGCTGCTATGAAGTCGACCGCTCGGGAAGTCTCTTTAACTCGGAGTGCAGCTTCCACTGCACTGAGCGGTACCAACTAAATGGGCCCAAG.
E L E L P Q E V L M N S H P L G N P S F N S Q S F H T D G Y Q V N G P S K

762 CTGGAATGCTTGGCTTCTGGAATCTGGCAAATAAGCTCCAGCTTTTACCTGCCAGTCCCACCTGAAGATCTCTGAACGAGGAACAATGATCTGCTTCTATTCTGCAAAAGCA
L E L A S G I W T N K P P Q L A A A Q P P L K I P E R G N M I L M S A K A

882 TTCACCATGAGTCTAGCTCGAGCTTCACTTGTGAAGAGGATTTGCATTACTTGGACCGGAAGTGTGSAATGCACAGCGCTCGGGGTATGGACAGCGCCAGCGCAGTGTGTAAAGCT
F Q W Q S S S F S E E G F A L V G P E V V Q T A S G V W T A P A P V C K A

→ AGHPE3

11002 CTGCAGTCTCAGCACTGGAAGCCCCAGCAAGCAACCATGAGTGTGTTTCATCGCTCACTGCTTTGCTATGGCTCAGCTGCAAAATTTAGTGCAGCGCGCTACAGAGTGAGG
V Q Q H L E A P S E G T H D V H P L T A P A Y G S S K F E Q P G Y R V R

111122 GGCTTGGACATGCTCGCTGATGACTCTGGACACTGCTCGACCTTGGCAACCTGTGAGGCTATTGTGTGAGCGCTGGAGACTCTGTCCAGCGAAGCATGGATTCTCTCCA
G L D H L R I D S G H W S A P L P I E A I S E P L E S P V M G S M D C S P

1242 TCCTTGAGCGTTTCAGTATGACACCAAGTCTAGCTTGGCTGCTGCTGAAGTTCAGCTCTGAGGACCGCATATAGTTGGTGTGTATTACTTGGGACAGTGTGGACAGCACCAGCCCA
S L R A P Q Y D T N S P R A E G F M L R G A D I V R D N L G Q W T A P A P

FIG. 2





FIG. 3



4/7




FIG. 4

5/7




FIG. 5

6/7

FIG. 6




FIG. 7





FIG. 8

-175	-136	
CAACATTACTCTTGCATTATCAACATTCTAACTTCATGG		P-selectin GATA
-----TTTAGA-----		Mutant
-344	-306	
CTTTAAATTGGAGCTTATATCATAATCCAAGGAAACCTT		Nonconsensus
GGCCTGGCCTTATCTCCGGCTGC		Endothelin-1 GATA

FIG. 9



A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/11 C12N15/85 C12Q1/68 C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PROC. NATL. ACAD SCI., vol.82, no.10, May 1985, NATL. ACAD SCI., WASHINGTON, DC, US; pages 3445 - 3449 Y.-K. PAIK ET AL. 'Nucleotide sequence and structure of the human apolipoprotein E gene' see figure 3 ---	7,8
X	J. BIOL. CHEM., vol.267, no.2, 15 January 1992, AM. SOC. MOL. BIOL., INC., BALTIMORE, US; pages 1279 - 1285 D.M. DORFMAN ET AL. 'Human transcription factor GATA-2' see page 1284, left column, line 25 - page 1285, right column, line 6 --- -/--	27,28

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

7 December 1994

Date of mailing of the international search report

22.12.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

HORNIG, H

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TRENDS IN BIOCHEMICAL SCIENCE, vol.17, no.4, April 1992, ELSEVIER SCIENCE, AMSTERDAM, NL; pages 135 - 140 V. BLANK ET AL. 'NF-kappaB and related proteins: Rel/dorsal homologues meet ankyrin-like repeats' cited in the application the whole document ---	1-30
A	TRENDS IN BIOCHEMICAL SCIENCE, vol.17, no.7, July 1992, ELSEVIER SCIENCE, AMSTERDAM, NL; pages 251 - 256 K. MACLEOD ET AL. 'The ets family' cited in the application the whole document ---	1-30
P,X	J. BIOL. CHEM., vol.268, no.30, 25 October 1992, AM. SOC. MOL. BIOL., INC., BALTIMORE, US; pages 22600 - 22608 J. PAN AND R.P. MCEVER 'Characterization of the promoter for the human P-selectin gene' see page 22600, left column, line 1 - page 22607, left column, line 16 -----	1-28